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MOLECULAR MECHANISMS OF MANGANESE PORPHYRIN COMPOUNDS IN THE 
PREVENTION OF RADIATION-INDUCED FIBROSIS 
Radiation therapy is frequently used as a treatment strategy for prostate cancer patients, 
which leads to several side effects due to damage to health tissue around the tumor and 
the development of radiation-induced fibrosis (RIF). Manganese (III) meso-tetrakis (N-
ethylpyridinium-2-yl) porphyrin (MnTE-2-PyP or T2E or BMX-010) and other similar 
manganese porphyrin compounds that scavenge superoxide molecules have been 
demonstrated to be effective radioprotectors and prevent the development of RIF. 
However, understanding of the radioprotective molecular pathway associated with these 
compounds remains limited. Recent RNA-sequencing data from our laboratory revealed 
that MnTE-2-PyP treatment may activate the nuclear factor erythroid 2-related factor 2 
(NRF2) signaling pathway. Therefore, we hypothesize that MnTE-2-PyP protects the 
prostate from RIF by activating the NRF2 signaling pathway. We identified that MnTE-2-
PyP is a post-translational activator of NRF2 signaling in prostate fibroblast cells, which 
plays a major role in fibroblast activation and myofibroblast differentiation. The mechanism 
of NRF2 activation involves an increase in hydrogen peroxide and a corresponding 
decrease in kelch-like ECH-associated protein 1 (KEAP1) levels. Further, we identified 
some of the key downstream effects of NRF2 pathway activation by MnTE-2-PyP 
treatment in prostate fibroblast cells. The downstream changes identified include an 
increase in expression of NAD(P)H dehydrogenase [quinone] 1 (NQO1), increase in 
nicotinamide adenine dinucleotide (NAD+) levels, increase in sirtuin activity (nuclear and 
mitochondrial), and increase in superoxide dismutase 2 (SOD2) expression/activity. 
An increase in mitochondrial sirtuin activity correlates with a decrease in SOD2 (K122) 





activity and mitochondrial superoxide scavenging capacity. Further, we identified changes 
in the consumption of mitochondrial substrates after radiation exposure that may correlate 
with mitochondrial health and protection mediated by MnTE-2-PyP. In the context of 
radiation exposure, MnTE-2-PyP fails to prevent fibroblast to myofibroblast transformation 
in the absence of NRF2 signaling. Collectively, our results indicate that the activation of 
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Chapter 1. Introduction 
1.1. Radiation exposure 
In physics, radiation is referred to any physical particle or wave that carries energy through 
space. Radiation waves are periodic variations of the electric and magnetic field intensity. 
Radiation waves can be classified into either high energy waves that have a low 
wavelength or low energy waves that have a high wavelength. Low energy – high 
wavelength radiation includes radiowaves, microwaves, infrared, and visible light. High 
energy – low wavelength radiation, which is also referred to as ionizing radiation includes 
ultraviolet, X-rays, and gamma-rays. Ionizing radiation has high tissue penetration power 
and is known to damage molecules in living systems by detaching electrons from atoms 
or molecules within a short span of exposure [2]. 
Life on Earth is continuously exposed to different kinds of radiation, and life has evolved 
in the presence of radiation. The duration, intensity (distance from the source), and type 
of radiation exposure can have a distinct effect on human health [3]. In medicine, ionizing 
radiation is used in cancer radiation therapy, dental care, nuclear medicine, and imaging 
for diagnosis. Further, humans can be exposed to higher than basal amounts of ionizing 
radiation during a nuclear explosion, air travel, mining of radioactive material, handling of 
nuclear power plant fuel, radioactive research laboratories, or space exploration [2]. 
Depending on the duration and intensity of ionizing radiation exposure, the human body 
can sometimes tolerate and repair itself from the damage caused by ionizing radiation. 
However, in situations where the body cannot tolerate or repair itself, therapeutic 
intervention is needed to prevent the damage caused to normal tissue and cancer 




In cancer radiation therapy, ionizing radiation (X-rays or γ-irradiation) is used to damage 
tumor cells and cause cell death. In the case of X-rays or γ-irradiation, ~70% of photons 
traversing a cell interact with water molecules that causes water radiolysis [5-7]. Radiation 
damage is then mediated through the displacement of electrons from atoms and 
molecules. Water lysis is followed by the formation of free radical species (unpaired 
electrons), reactive oxygen species (ROS) and reactive nitrogen species (RNS) that 
interact, damage or interfere with the normal functioning of macromolecules (DNA, lipids 
and proteins) [4]. The reactive molecules formed include hydroxyl radicals (•OH), 
hydroperoxy radicals (HOO•), hydrogen peroxide (H2O2), superoxide (O2•−) and 
peroxynitrite (ONOO−) [8]. An acute increase in ROS post-irradiation can also trigger a 
cycle of higher ROS generation through an increase in levels and activity of several 
prooxidant enzymes, such as NADPH oxidases (NOXs), cyclooxygenases (COXs), nitric 
oxide synthases (NOSs), and lipoxygenases (LOXs) [9]. This further contributes to tumor 
cell death or stalling in tumor growth. An unintended consequence of the damage caused 
to tumor cells by radiation therapy is the damage caused to normal tissue surrounding the 
tumor.  
1.2. Radiation therapy for prostate cancer treatment 
It is estimated that there was 174,650 new prostate cancer cases diagnosed in 2019 in 
the US [10]. About 109.5 per 100,000 men per year are diagnosed with prostate cancer 
based on 2012-2016 statistics. Further, in 2016, there were an estimated 3,110,403 men 
living with prostate cancer in the United States [11]. It is the second most diagnosed 
cancer and the second leading cause of cancer death in men in the United States [10]. 
The prostate is a part of the male reproductive system that functions to provide alkaline 




secretions provide lubrication and nutrition for the sperm. Semen is forced into the urethra 
by contraction of the prostate muscles during ejaculation [13, 14]. The prostate is located 
directly below the bladder and above the muscles of the pelvic floor [13-15]. It is in close 
vicinity to the rectum, seminal vesicles and seminal ducts, bladder, pelvic bone, prostatic 
plexus (nervous), and pudendal nerve [16]. The prostate gland is also surrounded by a 
capsule of connective tissue containing many smooth muscle fibers and elastic connective 
tissue, which makes it elastic in nature [17]. Therefore, it is essential to prevent damage 
to the prostate and the surrounding tissue after radiation therapy for prostate cancer 
patients.  
Depending on the stage of prostate cancer and other factors, radiation therapy might be 
used: as the first treatment without prostatectomy, as a part of hormone therapy, and as 
an adjuvant therapy to prostatectomy [18]. It is estimated that nearly half of all prostate 
cancer patients will undergo radiation therapy [19]. The current radiation treatment 
options, although effective, pose severe side effects that impact the quality of life of 
patients. Side effects of radiation therapy for prostate cancer include sexual dysfunction, 
genitourinary side-effects, bowel, and rectal wall damage, urinary urgency and frequency, 
urethral stricture, and incontinence [20-26]. The underlying cause for the development of 
these side-effects is due to the formation of fibrotic tissue [27-31]. Often, this fibrotic tissue 
remains unresolved and leads to a dysfunctional organ; this condition is known as 
radiation-induced fibrosis (RIF). To minimize the rectal injury to men undergoing radiation 
therapy, SpaceOAR hydrogel is used to provide space between the rectum and the 
prostate [32, 33]. This separation helps reduce the volume of normal tissue exposed to 
radiation and lowers rectal damage. However, other tissues are still susceptible to 
radiation damage and therapeutic interventions are still required to prevent sexual 




Nearly 50% of prostate cancer patients undergo radiation therapy as a treatment strategy 
and there are no FDA-approved drugs to either protect the surrounding tissues of the 
prostate or prevent the side-effects of radiation therapy. However, there are ongoing 
clinical trials for radioprotector drugs for other cancers, which can potentially be used for 
prostate cancer radiation therapy clinical trials.  
Radioprotectors are compounds that are designed to reduce the damage in normal tissues 
caused by radiation [4]. A good radioprotector protects normal cells without changing the 
tumor cell sensitivity to radiation damage. Amifostine, which generates a cytoprotective 
thiol metabolite in vivo, is an FDA-approved radioprotectant. It has also been carried by 
US astronauts on lunar missions as a radioprotector [34, 35]. However, its efficacy as a 
radioprotector has been heterogeneous and its use has led to development of several 
side-effects [36]. Some of the reported adverse side-effects of amifostine include nausea, 
vomiting, hypotension, hypocalcemia, diarrhea, sneezing, somnolence, hiccoughs and 
allergic reactions [36, 37]. Therefore, amifostine as a radioprotector has largely fallen out 
of use [36]. 
1.3. Radiation-induced fibrosis (RIF) 
As mentioned, radiation therapy effectively kills tumor cells through ROS generation, and 
can also damage nearby healthy tissues [9]. This results in the development of severe 
side-effects of radiation therapy and the formation of fibrotic tissue, which reduces patient 
quality of life. An increase in ROS after radiation exposure is a known driver for the 
development of fibrosis [38]. Fibrosis is characterized by an aberrant accumulation of 
extracellular matrix (ECM) proteins that result in the loss of normal tissue and organ 




The major cell type involved in developing fibrosis is the myofibroblast, which primarily 
arises from fibroblasts upon radiation exposure. Myofibroblasts can also arise from other 
cell types through the process of differentiation or by epithelial/endothelial-mesenchymal 
transitions [47, 48]. These differentiated fibroblasts have a phenotype that is closer to the 
smooth muscle cell and can be detected by measuring the expression of myofibroblast 
markers such as α-smooth muscle actin (α-SMA), paladin, desmin, and vimentin [49]. 
Every tissue has a balance between the number of fibroblasts and myofibroblasts that 
regulate the tissue functioning through different molecules that are secreted and provide 
structural support to surrounding cells by the production of ECM proteins. Further, it is 
estimated that myofibroblasts have a >200% increase in cell size and increased protein 
synthesis in comparison to normal fibroblasts [50]. The secretory factors produced include 
chemokines, cytokines, growth factors and inflammatory mediators that can promote the 
development of fibrosis [51].  
Under normal conditions, myofibroblasts play a critical role in wound closure after injury 
[52, 53]. After wound healing and restoration of ECM to homeostatic levels, these 
myofibroblasts undergo apoptosis [48]. However, wounds that fail to heal correctly contain 
persistent myofibroblasts that leave a keloidal or hypertrophic scar. These active 
myofibroblast cells do not undergo apoptosis after healing and continue to damage the 
tissues and organs by producing excessive amounts of ECM proteins. The persistent 
nature of an activated myofibroblast is maintained through molecular feedforward loops 
by autocrine and paracrine signaling and the influx of inflammatory cells [54, 55]. ROS 
from other sources, including ROS generating enzymes, and damaged mitochondria, are 
also involved in the maintenance of these myofibroblast cells [8]. Further, ROS generated 
after radiation exposure can drive epigenetic changes, metabolic changes and alter 




1.4. ROS drives the development of RIF 
As mentioned, ROS generation after radiation exposure is a driver for the development of 
RIF. An increase in ROS after radiation can occur through the radiolysis of water, 
mitochondrial damage, and an increase in expression of ROS generating enzymes 
through the activation of the TGF-β signaling pathway [9, 38, 60]. Thereby, setting up a 
vicious cycle of high oxidative stress, which drives epigenetic reprogramming of fibroblast 
cells to myofibroblasts (Fig. 1) [39, 61, 62]. 
The mitochondria are essential cellular organelles involved in regulating ROS levels and 
cellular metabolism that impacts the formation of myofibroblasts. Under normal metabolic 
conditions, the mitochondria produce low basal levels of superoxide via the electron 
transport chain, which is required for normal cellular signaling [63]. Ionizing radiation can 
directly damage mitochondrial DNA and nuclear DNA that codes for mitochondrial 
proteins, which leads to several functional changes in the mitochondrial structure, activity, 
and function [64-67]. Similarly, the lipid bilayer of cell membranes can be directly and 
indirectly damaged by ionizing radiation leading to apoptosis via an increase in membrane 
permeability and disruption of ion gradients [68, 69]. Radiation exposure can result in 
excessive production of mitochondrial ROS due to a loss in mitochondrial membrane 
integrity/potential or an increase in mitochondrial number [64, 70, 71]. Further, radiation-
induced mitochondrial damage reduces the production of tricarboxylic acid (TCA) 
metabolites and causes an increase in fatty acid metabolism. The mitochondria also 
regulate the generation of epigenetic metabolites such as nicotinamide adenine 
dinucleotide (NAD), α-ketoglutarate (α-KG), S-adenosyl methionine (SAM), and acetyl-
CoA [57, 58]. Therefore, damage to the mitochondria by radiation exposure can drive ROS 




The impact of ROS on TGF-β signaling is the most studied in the context of RIF [68, 73-
75]. An increase in ROS after radiation exposure leads to the activation of the TGF-β 
signaling pathway through the oxidation of cysteine residues of the latency-associated 
peptide (LAP). Oxidation of LAP leads to a conformational change in LAP, which allows 
the release of TGF-β from the latent complex. An active TGF-β, upon binding to TGF-β 
receptors, leads to the phosphorylation and activation of transcription factors, such as 
SMAD2 and SMAD3 [76]. TGF-β pathway stimulation increases the basal level of ROS 
through several NADPH oxidases (NOXs), including NOX4, via the canonical SMAD2/3 
signaling factors [77] and activation of PI3K [76, 78]. Generation of ROS through NOX4 
upregulation can also lead to the activation of the noncanonical SMAD signaling pathway, 
which includes the activation of c-Src and FAK kinases [79]. These changes in the TGF-
β signaling pathway and the crosstalk with the PI3K/AKT signaling pathway leads to 
changes in the epigenome and the development of fibrosis (Fig. 1) [61, 74]. 
Regarding genetic changes associated with the development of RIF in prostate tissue. 
There has been a study that analyzed the genetic predictors of late radiation-induced 
morbidity in prostate cancer patients by Schack, Line MH, et al., in 2017 [29]. In their 
research, they identified single nucleotide polymorphism (SNP), rs2682585 minor allele 
(A) in the follicle stimulating hormone receptor (FSHR) gene to be involved in resistance 
to fibrosis and had the lowest radiation-induced anorectal dysfunction score. In other 
tissue types, there are genetic mutations that are related to increased radiosensitivity, 





Figure 1. ROS drives the development of RIF. Radiation-induced ROS generation 
drives fibroblast reprogramming and the development of RIF. ROS can be directly 
generated due to radiolysis of water or through the damage of mitochondria. This leads 
to the activation of the TGF-β signaling pathway, which sustains an increase in ROS 
levels by increasing NOX4 expression, thereby setting up a vicious cycle of high 
oxidative stress, which drives epigenetic reprogramming of fibroblast cells to 
myofibroblasts. Further, damaged mitochondria have altered production of redox-
sensitive epigenetic metabolites that serve as cofactors for chromatin modifying 
proteins. NOXs, NADPH oxidases; NAD+, Nicotinamide adenine dinucleotide; SAM, S-









1.5. Antioxidants and antifibrotic agents used to prevent radiation-induced 
damage and fibrosis 
There have been several studies using different antioxidant and anti-fibrotic molecules in 
humans and small animal studies to prevent radiation-induced damage or fibrosis (Table 
1). The different tissue types studied for RIF include lung, small intestine, thyroid gland, 
salivary gland, head and neck tissues, brain, heart, kidney, eye, skin, colon, pelvic tissues 
(prostate and ovary), and breast tissues. Some of these studies show radioprotection upon 
whole-body radiation exposure, which would be applicable for instances of a nuclear 
disaster or fallout. The radiation dose in different studies ranges from a minimum of 2 Gy 
to a maximum of 37.5 Gy for small animals. Human beings generally receive a fractionated 
dosing scheme which adds up to a total of 20-80 Gy depending on the organ and tissue 
sensitivity to radiation damage. Maximum tumor damage and growth inhibition due to 
radiation damage is often not achieved due to the restriction in the maximum radiation 
dose (>80 Gy) that can be delivered without causing any side effects. Among the different 
molecules and agents shown in Table 1, SOD mimics or manganese porphyrin 
compounds were able to prevent radiation damage or RIF at a fractionated radiation dose 
ranging from 25-30 Gy in small animals. Other molecules such as amifostine, alpha-lipoic 
acid, curcumin, NAC, resveratrol and vitamin E generally protected different tissues at a 
radiation dose lower than 20 Gy, which again highlights the effectiveness of SOD mimics 
or manganese porphyrin compounds in prevention of RIF. Further, some of these 
compounds are used at a much higher dose (>10 mg/kg) in comparison to the manganese 
porphyrin compounds. Another issue associated with the natural compounds is their poor 
bioavailability, which restricts their use in different tissue types. 
To treat and prevent RIF, we can either remove the ROS generated after radiation 




1). However, inhibiting epigenetic alterations or TGF-β signaling can result in damage to 
other normal cells or organs that are not exposed to radiation. Therefore, boosting the 
antioxidant capacity of cells before radiation exposure would be the best strategy to 
prevent RIF with minimal side effects. Further, antioxidants can prevent activation of the 
TGF-β signaling pathway and/or epigenetic modifications observed after radiation 






Table 1. Antioxidants and antifibrotic agents used to prevent radiation-induced 
damage and fibrosis. Column 1, drugs or molecules that have been investigated to 
prevent radiation-induced damage and fibrosis. Column 2, tissue of region of body 
being exposed to radiation. Column 3, radiation dose used and studied in different 
animal models. Column 4, dose and scheme of drug usage. Column 5, cellular pathway 
or cellular changes or mechanism studied in the context of radiation damage and 


















28 Gy / 
Rats 
10-30 mg/kg/day, for 
10 weeks 





15 Gy / 
Mice 
100 mg/kg, 3 days 
before radiation 
Reduces inflammation and cell death, and 
reduces p-NF-κB, MMP9, and MAPK 
signaling. Facilitates regeneration of 
vitamin C and E and elevates glutathione 
levels [81].  
[82] 
Thyroid  
18 Gy / 
Rats 
100 mg/kg, 24 h 
before radiation 
Inhibits TGF-β signaling. [83] 
Salivary 
gland  
18 Gy / 
Rats 
100 mg/kg, 24 h 
before irradiation 
Reduces oxidative stress by inhibiting 








200 mg/m2 to 400 
mg/m2 
Thiol compound, free radical scavenger, 
reduces oxidative radicals, prevents 




22.5 Gy / 
Rats 
160 mg/kg, 15 
minutes before 
radiation 




200 mg/kg, 30 
minutes before 
radiation 
Prevents vasculitis and vascular injury. [88] 
Kidney  15 Gy 
200 mg/kg, 30 
minutes before 
radiation 
Prevents glomerular and tubular changes 




Atorvastatin Kidney  
2 Gy / 
mice 
50 mg/kg/day for 1 
week 










Prevents radiation-induced pulmonary 
fibrosis by shifting the imbalance of Th1 




18 Gy / 
Rats 
200 mg/kg/day, 1 
week before 
radiation 
Boosts antioxidant defenses by increasing 
HO-1. Prevents COX-2 upregulation, 




13.5 Gy / 
Mice 
1% or 5% (w/w) 
Prevents radiation-induced pulmonary 







5 Gy / 
Rats 
100 mg/kg/day 1 
week before 
irradiation by gastric 
tube 
Inhibits production of proinflammatory 









10 to 20.5 
Gy / Rats 
30 mg/kg, 30 
minutes before 
radiation 








12 Gy / 
Rats 
8 mg/kg/day 
Reduces oxidative damage, TGF-β and 
NF-κB signaling and activated 
macrophages. 
[97] 
Flaxseed Lung  
13.5 Gy / 
Mice 
10% (w/w) 
Reduces expression of lung injury 
biomarkers (Bax, p21, and TGF-β). 
Contains omega-3 fatty acids and lignans 
with antioxidant properties.  
[98] 
Follistatin Hindlimb  
35 Gy / 
Mice 
4 μg, 24 hours 
before, 2 days after 
radiation, and then 
3/week over 6 
months 










2 mg/kg before every 
fraction 
Protects liver in SIRT3−/− animals from 
radiation-induced injury. 
[100] 
GC4419 Oral cavity  
60 to 72 
Gy / 
Human 
15 to 112 mg/day, 
60 min before 
radiation for 3 to 7 
weeks 






12 Gy / 
Rats 
50 mg/kg/day 
Reduces oxidative damage, TGF-β and 






2,4 and 8 
Gy / Rats 
50 mg/kg/day for 10 
days 
Alleviates functional and structural 
alterations in kidney due to antioxidant 










Attenuates irradiation-induced oxidative 
organ injury, by preventing an increase in 
LDH and TNF-alpha levels. 
[103] 
Eye  
5 Gy / 
Rats 
40 mg/kg/day, 3 
days pretreatment 
and up to 7 days 
post-radiation 
Prevents increase in xanthine oxidase 




6 Gy / 
Rats 
50 and 100 
mg/kg/day for 7 days 
Corrects the metabolic disturbances 
induced in the brain by lowering 
dopamine, calcium and zinc contents 
while increasing in iron content. Restores 
the activities of lactate dehydrogenase 






12 Gy / 
Mice 
4 mg/kg/day 
Reduces TNF‑α, IL‑1β and IL‑6 production 
in serum via inhibition of NF‑κB and 
downregulates TLR‑4 and HMGB1 
expression in the lungs. Reduces ROS 
levels and HIF‑1α expression along with 
inhibition of NOX‑1 and NOX‑2 
expression. 
[106] 
Hesperidin Heart  
18 Gy / 
Rats 
100 mg/kg/day for 7 
days 
Decreases inflammation, fibrosis, mast 
cell and macrophage numbers, and 





35 Gy / 
Mice 
50uL of formulation, 
0.5, 24 and 48h after 
radiation 






13.5 Gy / 
Mice 
120 mg/kg twice 
daily 







6-7 Gy / 
Rats 
30, 10, 3 mg/kg/day, 
3 days before or 
after radiation 
Reduces radiation-induced damage by 
altering 21 pathways. 
[110] 
Melatonin Lung  
18 Gy / 
Rats 
100 mg/kg once 30 
minutes before 
radiation 








28 Gy / 
Rats 
0.05 mg/kg/day for 2 
weeks, 2 h post-
radiation 
Decreases HIF-1alpha, TGF-β, and VEGF 
A expression after radiation. 
[112] 
Lung  
28 Gy / 
Rhesus 
monkeys 
0.05 mg/kg twice 
daily for 2 months 







10 Gy / 
Mice 
6 mg/kg/day, Day 1 
to 16 
Inhibits TGF-β signaling. Protects against 





20-30 Gy / 
Rats 
5 mg/kg/week, 1 h 
before radiation 






37.5 Gy / 
Mice 
10 mg/kg/week, 24 h 
before radiation. For 
the first two weeks, 3 
times/week at a 
dose of 5 mg/kg 
Reduces collagen deposition, 
inflammation, senescence, fibroblast to 
myofibroblast differentiation and 
upregulates NQO1 expression. 
[117] 
Lung  
28 Gy / 
Rats 
6 mg/kg/day, 15 min 
before radiation 
Inhibits TGF-β signaling. [118] 
Lung  
28 Gy / 
Rats 
6 mg/kg/day for 10 
weeks 
Decreases HIF-1alpha, TGF-β, and VEGF 












5 Gy / 
Mice 
1.5 mg/kg, twice 
daily, for 14 days 
Protects hippocampal neurogenesis. [120] 
Brain  
8 Gy / 
Mice 
1.6 mg/kg, twice 
daily, 24 h before 
radiation 





2 Gy / 
Mice 
0.25 μM every 3 
days, for in vitro 
studies 
Prevents activation and increase in cell 







18 Gy / 
Mice 
500 mg/kg/day, 3 
days before and up 
to 3 days post-
radiation 
Protects the lung and red blood cells from 




6 Gy / 
Rats 
1000 mg/kg, 15 min 
before radiation 
Protects rat femoral bone marrow cells 




10 Gy / 
Rats 
300 mg/kg/day 
Alleviates the negative effects of 
radiotherapy on incisional wound healing 




20 Gy / 
Mice 
300 mg/kg/day, for 7 
days 
Prevents gastrointestinal injury, damage to 
bone marrow stromal cells and radiation-








30 Gy / 
Mice 
5.4 μg/kg/day for 18 
weeks beginning 2 
days before 
radiation 
Prevents RIF with increased fibrin 
metabolism, enhanced matrix 
metalloproteinase-3 expression, and 





16 Gy / 
Mice 
300 mg/kg/day for 
four weeks 
Inhibits TGF-β signaling. 
[128] 
Intestine  
20 Gy / 
Mice 
200, 400 mg/kg/day 
















11 Gy / 
Mice 
5 mg/kg once 




15 Gy / 
Mice 
100 mg/kg/day 
Exerts anti-inflammation and anti-oxidative 





13 Gy / 
Mice 
100 mg/kg/day for 6 
days before and 
after radiation 




35 Gy and 








7 Gy / 
Mice 
40 mg/kg/day, 1-day 
pretreatment and up 
to day 5 
Prevents intestine damage via the 
activation of Sirt1. Improves intestinal 
morphology, decreases apoptosis of crypt 
cells, maintained cell regeneration, and 
ameliorated SOD2 expression and activity. 
Regulates Sirt1 and acetylated p53 




3 Gy / 
Mice 
100 mg/kg/day, 2 
days pretreatment 
and up to 30 days 





15 Gy / 
Mice 
20 mg/kg/day 
Inhibits TGF-β signaling. Protects salivary 






25 mg/kg/day for 2 
weeks 
Counteracts the effect of radiation and 
upregulates the gene expression of 
PPAR-γ and SIRT1, leading to inhibition of 






6 Gy / 
Mice 
20 mg/kg/day for 7 
days before and 
then up to 30 days 
post-radiation 
Protects from radiation-induced injury, in 








35 Gy / 
Mice 
1% by weight Inhibits TGF-β signaling. [134] 
Lung  
13 Gy / 
Mice 
100 mg/kg/day for 7 
days 
Prevents lung injury by reducing 
inflammation and fibrosis. 
[141] 
rhNRG-1β Heart  
20 Gy / 
Rats 
15 μg/kg 3 days 
before and 7 days 
after radiation 
Prevents fibrosis and preserves cardiac 
function via the ErbB2-ERK-SIRT1 
signaling pathway. 
[142] 




400 IU for 6 months 
Vitamin E may be clinically useful in 





Hind leg / 
Skin  
25 Gy / 
Mice 
10,000 units/kg/day 
for 8 days 







77.5 Gy / 
Humans 
200 mg tablet 
containing (50 mg 
soy isoflavones; 
genistein:daidzein:gl
ycitein at a ratio of 
1.1:1:0.2) 
Reduces the urinary, intestinal, and sexual 
adverse effects in patients with prostate 
cancer receiving radiation therapy. 
[145] 
Lung  
12 Gy / 
Mice 
50 mg/kg/day, 3 
days before and up 
to 4 months after 
radiation 
Mitigates inflammatory infiltrates and 
radiation-induced lung injury. 
[146] 
Lung 10 Gy 
250 mg/kg/day, 3-
day pretreatment 
Inhibits the infiltration and activation of 
macrophages and neutrophils induced by 
radiation in lungs. 
[147] 
Lung 




and up to 4 months 
after radiation 
Inhibits the infiltration and activation of 
macrophages and neutrophils induced by 




14 Gy / 
Mice 
32 mg/kg/day 
Inhibits TGF-β signaling. Taurine essential 
amino acid is involved in osmoregulation, 
anti-oxidation, detoxification, membrane 
stabilization, neuromodulation, cardiac 




6 Gy / 
Rats 
2 oral doses of 
500 mg/kg/day for 2 
weeks 
Taurine has antioxidant, anti-inflammatory, 













20 Gy / 
Rats 
2.5% of diet 2 weeks 
before radiation or 
150 mg injected 4 h 
before radiation 




14 Gy / 
Rats 
1.1 mg/day 
dissolved in 0.1 ml 
olive oil injected 
Protects against the development of RIF. [152] 
Whole-
body 
9.2 Gy / 
Mice 
50 mg/kg 24 h 
before radiation 
Protects against acute radiation 
syndrome. 
[153] 
SKI2162 Hind limb  
22 Gy / 
Mice 
10 mg/kg/day, 5 
times/week 
An inhibitor of the TGF-β type I receptor 
(ALK5), inhibits radiation-induced fibrosis. 
[154] 
GV1001 Skin  
6 Gy / 
Mice 
1 mg/kg/day and 5 
mg/kg/day for 4 
weeks 
Suppresses TGF-β signaling. [155] 
XH-103 Intestine 
11 Gy / 
Mice 
200 mg/kg, 1 before 
radiation 









1.6. Role of superoxide removal by superoxide dismutase and manganese 
porphyrin compounds in preventing RIF  
Superoxide (O2•−) is an anionic ROS that contains an extra electron in comparison to 
molecular oxygen [157]. Molecular oxygen has two unpaired electrons, whereas 
superoxide has one unpaired electron. Superoxide is produced in all cells by the one-
electron reduction of oxygen [158]. This can happen intracellularly either through the 
mitochondria or through the normal catalytic function of enzymes such as NADPH 
oxidases, xanthine oxidases, and cytochrome P450 family. Environmental factors such as 
UV light, cigarette smoke, environmental pollutants, and ionizing radiation exposure are 
known to increase superoxide levels [158, 159]. Apart from RIF, excessive amounts of 
superoxide generation plays a major role in the development of cancer, atherosclerosis, 
rheumatoid arthritis, diabetes, liver damage, and central nervous system disorders [160, 
161]. An increase in superoxide levels leads to cellular toxicity and is a strategy used by 
immune cells to kill microorganisms in phagocytes [162]. Further, superoxide can react 
with nitric oxide, forming peroxynitrite species (ONOO-, ONOOH), these proxynitrite 
species can decompose to yield the hydroxyl radical (•OH) and the nitrogen dioxide radical 
(•NO2), which are all very reactive and highly oxidizing species [161]. Therefore, levels of 
superoxide within cells needs to be tightly controlled and kept at low levels.  
To combat superoxide toxicity, all human cells express three superoxide dismutase 
(SODs) enzymes. In a two-step reaction, these enzymes convert two molecules of 
superoxide into hydrogen peroxide (H2O2) and oxygen [163]. The three enzymes that 
perform this reaction are SOD1 (Cu/ZnSOD), SOD2 (MnSOD), and SOD3 (Ec SOD). 
SOD1 binds copper and zinc ions and functions as a homodimer that is located in the 
cytosol and the intermembrane space of the mitochondria [164]. SOD2, binds one 




SOD3 or Ec-SOD, is a tetrameric protein and is found in the extracellular matrix of tissues. 
Loss of SODs is associated with several human pathologies, including pulmonary fibrosis, 
cardiovascular and degenerative neurological diseases [165, 166]. Therefore, there has 
been a need to develop and test compounds that reduce superoxide levels for different 
therapeutic applications in medicine.  
Manganese porphyrin compounds are small water-soluble compounds that scavenge 
superoxide molecules [167]. It has taken three decades of work to design and synthesize 
these compounds that mimic the activity of native SOD enzymes for clinical use [168]. 
They have a catalytic active site similar to SOD2 (MnSOD) enzyme and catalyze the two-
step reaction: (1) MnIIIP5+ + O2•- ⇌ MnIIP4+ + O2, and (2) MnIIP4+ + O2•- + 2H+ ⇌ MnIIIP5+ + 
H2O2 [163]. Apart from superoxide scavenging, these compounds are also known to reduce 
lipid peroxides, peroxynitrite levels, and catalyze other diverse redox reactions [168]. 
Therefore, manganese porphyrin compounds are being studied for their application in 
diseases involving superoxide and oxidative stress [169].  
MnTE-2-PyP5+ (BMX-010), belongs to the category of manganese porphyrin compounds 
[167, 170-175]. MnTE-2-PyP, along with its sister molecules, such as, MnTnBuOE-2-
PyP5+ [120], MnTnHex-2-PyP5+ [176-178] and MnTDE-2-ImP5+ have been shown to be 
effective radioprotectors. In our laboratory, we have shown both MnTE-2-PyP and 
MnTnBuOE-2-PyP protect from radiation-induced fibrosis by preventing the 
transformation of fibroblasts to myofibroblasts. Further, we have shown that MnTE-2-PyP 
reduces chronic fibrosis and inflammation in irradiated normal pelvic tissue [179].  
In our laboratory, we use two of the manganese porphyrin compounds; MnTE-2-PyP (Fig. 
2: A) and MnTnBuOE-2-PyP (Fig. 2: B) which have similar molecular structures with the 
only difference being the lipophilic side chains of MnTnBuOE-2-PyP . The lipophilic side 




the dose required for treatment (0.5 μM) to achieve the same amount of reduction in 
superoxide molecules. Currently, MnTnBuOE-2-PyP5+ (BMX-001), is in Phase I/II clinical 
trials as a radioprotector of normal tissues in head and neck (NCT02990468), 
glioblastomas cancer patients (NCT02655601), anal cancer treatment (NCT0338650), 
and brain metastasized cancers (NCT03608020) [180, 181]. Another SOD mimic 
compound, GC4419, has been shown to be an effective radioprotector and is in clinical 
trials (NCT02508389, NCT01921426, and NCT03689712) [182, 183]. In addition to 
radioprotection, these manganese porphyrin compounds have been reported to have anti-
tumor effects.  
Manganese porphyrin compounds do not protect cancer cells and acts as a sensitizer to 
radiotherapy and chemotherapy. In cancers of the prostate, breast, brain, colon, ovarian 
and, head and neck, the levels of ROS are higher in comparison to the surrounding normal 
tissue [123, 168, 175, 184-190]. This makes these cancer cells more susceptible to ROS 
mediated cell death when treated with a combination of manganese porphyrin compounds 
and chemo- or radiotherapy, which are involved in generating ROS. Further, accumulation 
of MnTE-2-PyP in tumor was found to be 7-fold higher in comparison to the normal tissue, 
which contributes to its anticancer effect [190]. In lymphoma, anti-cancer activity was 
achieved by manganese porphyrin compounds by suppressing mitochondrial and 
glycolytic energy sources of cancer cell [191]. Further, an increase in S-glutathionylation 
of p65 subunit of NF-κB by the H2O2 generated by manganese porphyrin compounds 
contributes to its anticancer activity [192].  
Given that these compounds do not protect tumors from radiation damage and are 
effective radioprotectors [172], we need to understand the molecular pathways and 
mechanisms through which they work. The consequences of boosting cellular capacity to 




understand the redox-sensitive pathways. Identification of the pathways on which these 
drugs work would help us further develop these compounds, potentially reverse fibrotic 













Figure 2. Structure of manganese porphyrin compounds used to remove 
superoxide and prevent the development of RIF. (A) Structure of MnTE-2-PyP or 
BMX-010 (CASRN 219818-60-7, Molecular Weight 965.13). (B) Structure of 












1.7. Signaling pathways altered by manganese porphyrin compounds 
Similar to SOD enzymes, manganese porphyrin compounds catalyze the conversion of 
superoxide molecules to hydrogen peroxide. Hydrogen peroxide has the most prolonged 
half-life of all ROS and is less reactive in comparison to superoxide [193]. An increase in 
hydrogen peroxide levels can lead to reversible oxidation of cysteine thiols to sulfenic 
acids (R-SOH) and sulfinic acid (R-SO2H), and further irreversible post-translational 
modification to sulfonic acid (R-SO3H). Alternatively, R-SOH modification can react with 
free protein thiols to form intra- or intermolecular disulphide bonds (R-S-S-R/R-S-S-R′) or 
is modified by glutathione (GSH) to form S-glutathionylation post-translational modification 
[194].  
Hydrogen peroxide is a central redox signaling molecule that can diffuse across 
membranes and can serve as an “oxidative eustress molecule” at low concentrations (1-
10 nM) or physiological steady-state levels [173, 195]. The term “oxidative eustress” 
means normal signaling of oxidative stress and serves as a distinction from excessive 
load, “oxidative distress”, which is known to cause oxidative damage [195]. At high 
concentrations (>100 nM), hydrogen peroxide can damage cellular structures and activate 
cell death pathways. Further, hydrogen peroxide can activate adaptive stress responses 
such as the nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway or nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [195] or activate 
apoptotic pathways for removal of damaged cells [196, 197]. Therefore, manganese 
porphyrin compounds can act as oxidants or antioxidants depending on the concentration 
used and the cellular microenvironment [168].  
Our group has previously shown MnTE-2-PyP treatment inhibits the TGF-β1 signaling 




mechanism of inhibition of the TGF-β1 signaling pathway is not completely understood. 
Further, MnTE-2-PyP and its sister molecules have been shown to inhibit the NF-κB 
signaling pathway [192, 199-202], and hypoxia-inducible factor-1 alpha (HIF-1α) [62, 114, 
203-205]. Recent reports also suggest that manganese porphyrin compounds can activate 
NRF2 signaling in hematopoietic stem cells [206]. Therefore, there could be crosstalk 
between these pathways and identification of the early changes in fibroblast cells would 
be essential to understand radioprotective mechanisms.  
1.8. The role of the NRF2 signaling pathway in radioprotection 
NRF2 or Nuclear factor erythroid 2-related factor 2, is a basic leucine zipper (bZIP) 
transcription factor that is responsible for the expression of several downstream targets 
such as NQO1, heme oxygenase 1 (HMOX1), glutamate-cysteine ligase catalytic subunit 
(GCLc), thioredoxin reductases (TrxR), glutamate-cysteine ligase modifier subunit 
(GCLm), glutathione peroxidases (Gpx) and other genes [207-209] that are involved in 
redox balance, purine metabolism, pentose metabolism, lipid metabolism, inflammation, 
and proteostasis [210, 211].  
The NRF2 protein consists of 605 amino acids and 7 recognized NRF2-ECH homology 
(Neh) domains (Fig. 3: A). These domains are responsible for interacting with different 
binding partners and its role in cellular functioning. Neh1 domain contains the cap “n” collar 
– basic-region leucine zipper (CNC-bZIP) region, which interacts and binds to antioxidant 
response elements (ARE) DNA elements (5′-TGACXXXGC-3′ or 5′-AGTGAXXCAGCA-3′) 
of the downstream targets. The Neh1 domain also interacts with the small 
masculoaponeurotic fibrosarcoma (sMaf) proteins (MafF, MafG, and MafK), which are 
NRF2 dimerization partners. The DLG and ETGE amino acid motifs of Neh2 domain 




is the negative regulator of NRF2. KEAP1 is a redox-sensitive adaptor protein, which binds 
to the Cul3/Rbx1/E2/ubiquitin ligase complex that ubiquitinates seven lysine residues of 
NRF2 in Neh2 domain and subjects it to proteasomal degradation. Neh3, Neh4 and Neh5 
domains are transactivation domains of NRF2 that bind to CREB-binding protein (CBP), 
ras-related C3 botulinum toxin substrate 3 (RAC3), and chromodomain Helicase DNA 
Binding Protein 6 (CHD6) proteins. The Neh6 domain is a serine-rich region that binds to 
β-transducing repeat-containing protein (β-TrCP), which negatively regulates NRF2 
stability independent of KEAP1, upon glycogen synthase kinase-3β (GSK3β) mediated 
phosphorylation of DSGIS and DSAPGS peptide motifs of Neh6 domain. Phosphorylation 
of the Neh6 domain leads to the recruitment of Skp1-Cul1-F-box protein (SCF) ubiquitin 
ligase complex which regulates NRF2 proteasomal degradation. The Neh7 domain 
interacts with retinoid X receptor α to repress NRF2 transcriptional activity. KEAP1, Kelch 
domain, that interacts with NRF2, also interacts with Sequestosome-1 (SQSTM1), which 
is a scaffold for binding of several proteins and regulates autophagy. The intervening 
region (IVR) domain of KEAP1, is redox sensitive and the cysteine residues (C272 and 
C288) of this domain are subjected to several different post-translational modifications. The 
broad complex, tramtrack and bric-à-brac (BTB) domain, is involved in KEAP1 
dimerization and the C151 residue of this domain also appears to be a key redox sensor 
(Fig. 3: B). 
Canonical NRF2 signaling is maintained at homeostatic levels through its cytoplasmic 
binding partner KEAP1, which prevents its translocation to the nucleus and ensures 
proteasomal degradation [212-214]. The non-canonical NRF2 signaling pathway is 
regulated by changes in protein levels and phosphorylation (Ser349) of SQSTMq, which 
is also known as p62 [212]. SQSTM1 competitively binds to KEAP1, which leads to KEAP1 




ubiquitin-binding protein that is involved in the regulation of cell signaling, oxidative stress, 
and autophagy [216, 217]. Importantly, lack of SQSTM1 or impairment of autophagy can 
result in the accumulation of damaged mitochondria and increased production of ROS that 
can further enhance fibroblast activation or formation of myofibroblast phenotype [218-
222]. 
The role of NRF2 in response to radiation exposure in healthy tissue has been reviewed 
by Cameron et al., in 2018, and it highlights the variability in different human tissues [223, 
224]. The NRF2 signaling pathway plays a significant role in fibroblast reprogramming and 
the expression of a senescence-promoting matrix [225]. In the context of radiation 
exposure and lung fibrosis, NRF2 is involved in the crosstalk and suppression of the 
transforming growth factor-beta 1 (TGF-β1) signaling pathway, which is the most well 
studied pro-fibrotic pathway [226-228]. An active NRF2 protein is known to form a nuclear 
complex with pSMAD3 at the CAGA site in the proximal promoters of TGF-β target genes 
and suppresses their expression [229]. The crosstalk between SIRT1 and the NRF2 
pathway forms a positive feedback loop to inhibit the expression of fibronectin (FN) and 
TGF-β1 [230]. Conversely, loss of NRF2 promotes TGF-β/Smad signaling that induces 
activating transcription factor 3 (ATF3) mediated suppression of NRF2 target genes. this 
crosstalk with the TGF-β1 signaling could play a role in the development of RIF. Previously 
observed radioprotective properties of MnTE-2-PyP and changes in TGF-β1 signaling 
pathway could be linked to changes in the NRF2 pathway in prostate fibroblast cells. 
Therefore, we hypothesize that MnTE-2-PyP protects the prostate from RIF by activating 
the NRF2 signaling pathway. 
The goal of this thesis is to investigate the molecular pathways and anti-fibrotic 
mechanisms of manganese porphyrin compounds such as MnTE-2-PyP. We will probe 




compounds in normal tissue and radiosensitive effects in cancer cells. We want to use this 
information to further enhance and optimize the use of manganese porphyrin compounds 










































Figure 3. NRF2 and KEAP1 binding partners and domain functions. (A) Human 
NRF2 protein comprises of 7 Neh domains. Their respective binding partners are 
shown. (B) Human KEAP1 protein comprises 4 domains. Their respective binding 
partners are shown. Neh, Nrf2-ECH homology; CNC-bZIP, cap “n” collar - basic-region 
leucine zipper; NTR, N-terminal region; BTB, Broad complex, Tramtrack and Bric-à-

















Chapter 2. Materials and methods 
2.1. Cell lines and tissue culture 
Mouse primary prostate fibroblast (MPF) cells were isolated from the prostate tissue of 6–
8-week-old C57BL/6J mice (wild type) or C57BL/6J Nfe2l2tm1Ywk (NRF2) knockout mice, 
as previously published [1]. Briefly, prostates were minced and digested with 5 mg/mL 
collagenase I for 30 min at 37 °C (17100017, ThermoFisher). These cells were cultured in 
DMEM media supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin and 1% nonessential amino acids [1]. MPF cells were pretreated 
with 30 μM MnTE-2-PyP for 24 hours, followed by 2 Gy radiation exposure and then 
collected 24 hours post-irradiation. Immortalized healthy human prostate fibroblast cells 
(P3158) were obtained from Dr. McDonald J. Tyson. Immortalization was performed by 
using pBABE-hygro-hTERT plasmid, a gift from Dr. Robert Weinberg (Addgene, plasmid 
#1773, Cambridge, MA, USA). These cells were cultured in RPMI-1640 medium, 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Normal 
human primary prostate fibroblast (HPrF) cells were purchased from ScienCell Research 
Laboratories (4430). HPrF cells were cultured in Fibroblast Medium (2301) on poly-L-
lysine coated flasks (2 µg/cm2) according to the protocol provided by ScienCell Research 
Laboratories. KEAP1 knockout mouse embryonic fibroblast cells and wild type cells were 
derived from C57BL6 mice and were a kind gift from Dr. Thomas Kensler’s laboratory at 
Fred Hutchinson Cancer Research Center (Dr. Nobunao Wakabayashi) [231]. All 
fibroblast cells were treated with or without 30 μM MnTE-2-PyP, 24 hours before radiation 




2.2. Real-time quantitative PCR (RT-qPCR) 
RNA was isolated from P3158 cells with the ZR RNA MicroPrep RNA isolation kit (R1065, 
Zymo Research) according to the manufacturer’s protocol. For quantitative analysis of 
mRNA expression, comparative real-time PCR was performed with the use of Power 
SYBR Green RNA-to-CT 1 step kit (4389986, ThermoFisher). Quantitative PCR was 
performed under the following conditions: 48 ºC for 30 min, 95 ºC for 10 min, then 40 
cycles with 95 ºC for 15 sec and 60ºC for 1 min. PCR primers obtained from Invitrogen 




Table 2. List of primers used for RT-qPCR. 
























































2.3. Collagen contraction assay 
The same procedure was followed for the collagen contraction assay, as previously 
published [1]. Briefly, human or mouse prostate fibroblast cells (1 x 105) were embedded 
in 2 mg/mL of rat tail collagen (354249, Corning) discs on low-attachment 24-well plates. 
After 8 hours of incubation, the collagen discs were observed for contraction and imaged. 
Areas of collagen discs were measured using ImageJ.  
2.4. Western blotting  
Cell lysates were prepared using 1x Cell Lysis Buffer (9803S, Cell Signaling Technology). 
Cell lysates (40-80 μg) were separated by electrophoresis using Bolt™ 4-12% Bis-Tris 
plus gels (NW04120BOX, ThermoFisher). Gels were transferred onto nitrocellulose 
membranes for blotting using the iBlot™ Transfer Stack (IB301002) and the iBlot 2 Dry 
Blotting System (ThermoFisher). For COL3A1 blotting, polyvinylidene difluoride (PVDF) 
membranes were used for transfer. To measure protein loading and transfer, we used 
Ponceau S staining for nitrocellulose membranes and a reversible protein stain kit for 
PVDF membranes (1858784, ThermoFisher). Blots were incubated with blocking buffer 
5% nonfat dried milk in Tris Buffered Saline with Tween 20 (TBST). Primary antibody 
incubation was performed overnight in 3% nonfat dried milk in TBST. Primary antibodies 
used in this paper include; NRF2 (ab62352), p-SQSTM1 (Ser349) (ab211324), SQSTM1 
(ab56416), SOD2 (ab13533), SOD2 (acetyl K68) (ab137037), SOD2 (acetyl K122) 
(ab214675), NOX4 (ab133303), and α-smooth muscle actin (ab5694) were obtained from 
Abcam (Cambridge, MA, US), NQO1 (NB200-209) was obtained from Novus Biological, 
and KEAP1 (D6B12) was obtained from Cell Signaling Technology, Inc. (Danvers, MA, 




(A24537, ThermoFisher), anti-mouse (A24524, ThermoFisher). Pierce ECL Western 
Blotting Substrate (80196, ThermoFisher) and SuperSignal™ West Dura Extended 
Duration Substrate (34076, ThermoFisher).  
2.5. Gene silencing 
Transfections of siRNAs were performed using Lipofectamine RNAiMAX Transfection 
Reagent (13778150, ThermoFisher) according to the manufacturer's instructions for 
transfecting adherent cells. Briefly, transfection complexes were formed at RT using 20 nM 
of siRNA, 7.5 μL of RNAiMAX, and 500 μL Opti-MEM I – Gibco (31985-062, 
ThermoFisher). Transfection complexes were added, and the mix was incubated with cells 
for 24 h using standard cell culture conditions. Negative control scrambled siRNA (Scr) 
(4390843, Ambion), Nfe2l2 (NRF2) siRNA (4392421, Ambion), NQO1 siRNA (43261843, 
Invitrogen), and SQSTM1 siRNA (AM16708, ThermoFisher) were used in the 
experiments. 
2.6. NAD+/NADH assay 
To measure changes in NAD+/NADH levels, we used the NAD+/NADH-Glo™ 
Bioluminescent Assay (G9071, Promega). In the presence of NADH, a reductase provided 
with the assay reduces a proluciferin reductase substrate to luciferin. Luciferin is quantified 
using Ultra-Glo™ Recombinant luciferase and the light signal produced is proportional to 
the amount of NAD+ or NADH in the sample. P3158 cells were pretreated with MnTE-2-
PyP (30 µM) for 24 hours before radiation (5 Gy) and collected 48 hours after radiation. 
5000 cells were suspended in 50 µl of PBS and mixed with 1% dodecyltrimethylammonium 
bromide solution as directed by the protocol by Promega’s NAD/NADH-Glo™ Assay. After 




after the addition of the 100 µl of NADP/NADPH-Glo™ detection reagent. Luminescence 
was recorded using the Infinite M200 Pro plate reader (Tecan). 
2.7. Sirtuin activity assay 
To measure changes in sirtuin activity, we used BioVision’s sirtuin activity assay kit 
(Fluorometric, K324-100, BioVision). Nuclear extracts were made 48 hours after radiation 
using the CelLytic NuCLEAR extraction kit (NXTRACT-1KT, Sigma), and 1 μg of nuclear 
extract was used to measure sirtuin activity. Trichostatin A is added to the reaction to 
specifically inhibit the activity of HDAC’s in samples. Mitochondrial extracts were made 
using the Mitochondria Isolation Kit for Cultured Cells (89874, ThermoFisher). Briefly, 1.5 
× 106 cells/ T75 flask were seeded with MnTE-2-PyP (30 µM) and after radiation exposure, 
cells were collected for isolation of nuclear, cytoplasmic, and mitochondrial fractions 
according to manufacturer’s instructions. Samples were mixed with a sirtuin activity buffer 
containing DTT ± TSA according to the protocol from BioVision’s sirtuin activity assay kit. 
Fluorescence was measured using the Infinite M200 Pro plate reader (Tecan) at Ex/Em = 
400/505 nm. Background control reading was subtracted from sample reading, and the 
corrected sample reading was measured against the AFC standard curve. 
2.8. Dihydroethidium (DHE) assay 
To measure superoxide levels and total ROS, cells were stained by dihydroethidium 
(D11347, DHE, 5 μM) for 20 min at 37 °C in the dark and then subjected to flow cytometric 
analysis using a LSRII Green 532 Flow Cytometer (BD Biosciences). To measure 
superoxide specifically, 405/570 nm excitation/emission was used. Data was analyzed 
using FACSDiVa analysis software (BD Biosciences). To measure total ROS, 488/540 nm 




2.9. NRF2 enzyme-linked immunosorbent (ELISA) assay  
NRF2 activity was determined using the TransAM NRF2 assay (50296, Active Motif) 
according to the manufacture’s protocol. Briefly, nuclear extracts (5 μg) were incubated 
with ARE consensus site oligonucleotides (5′-GTCACAGTGACTCAGCAGAATCTG-3′); 
immobilized to 96-well plates. Bound protein was detected with an antibody specific to 
DNA-bound NRF2 and visualized by a colorimetric reaction catalyzed by horseradish 
peroxidase-conjugated secondary antibody, and absorbance was measured at 405 nm 
using the Infinite M200 Pro plate reader (Tecan).  
2.10. NRF2 Electrophoretic mobility shift assay (EMSA) 
For studying the DNA binding activity of NRF2, nuclear extracts were made as described 
[232, 233]. Promega Gel Shift Assay Core System (E3050, Promega) and used NRF2 
consensus oligonucleotide from NF-E2 gel shift oligonucleotides product from Santa Cruz 
Biotechnology (sc-2527). Thirty-five pmol of each consensus oligonucleotide was labeled 
by P32-ATP by T4-polynucleotide kinase according to the Promega protocol. After 
purification of labeled consensus oligonucleotide, 10 µg nuclear protein was incubated 
with the oligonucleotides and run in 6% TBE gel (EC6265BOX, ThermoFisher) according 
to the Promega gel shift assay system protocol. Then the gels were air-dried overnight 
using Model 583 gel dryer backing cellophane (1650963, BIO-RAD) and a gel drying 
cassette. The dried gel with the cellophane were then exposed to film. Films were scanned 




2.11. ROS-GLO H2O2 assay 
Hydrogen peroxide (H2O2) generated by MnTE-2-PyP was measured using the ROS-GLO 
H2O2 assay (G8820, Promega) as previously described [234]. Briefly, HPrF cells (1 × 104 
cells/well in 70 µl of HPrF media) were seeded in a Nunclon 96 Flat White Plate 
(ThermoFisher). MnTE-2-PyP time course treatment was performed by the addition of 10 
µl of MnTE-2-PyP (30 µM) or PBS. Six hours before measurement of H2O2, 20 µl H2O2 
substrate and H2O2 dilution buffer were added to each well. At the end of the MnTE-2-PyP 
time course treatment, 100 µl ROS-GLO™ Detection Solution was added to each well and 
all samples were incubated at room temperature for 20 min. Luminescence was read by 
the Infinite M200 Pro Plate Reader (Tecan) using an integration time of 1000 ms. 
2.12. SOD2 in-gel activity assay 
SOD2 activity was monitored with non-denaturing gel electrophoresis, as previously 
described [235]. Briefly, whole-cell protein lysate (100 μg) were separated in a 10% native-
PAGE gel and stained by riboflavin, nitroblue tetrazolium, and TEMED. SOD2 activity was 
differentiated from SOD1 activity by inhibiting SOD1 activity with the use of sodium 
cyanide in the staining solution. SOD2 activity bands were developed overnight under 
exposure of light. Images were taken and the density of the band was measured to obtain 
the relative SOD2 activity.  
2.13. Xanthine oxidase - SOD activity assay 
SOD activity assay was measured in mitochondrial extracts using a xanthine oxidase - 
SOD activity assay kit (K335-100, BioVison). Briefly, 5 μg of mitochondrial extract in 20 μl 




solution and 20 µl of the SOD enzyme working solution were added to the sample wells 
and mixed thoroughly. The solution was incubated at 37°C for 20 minutes. The 
inhibition/reduction activity of SOD was estimated by measuring absorbance at 450 nm 
using the Infinite M200 Pro plate reader (Tecan). 
2.14. Cell size analysis 
Fibroblasts were seeded at 1 × 105 cells/T-25 flask. Cells were treated with PBS, MnTE-
2-PyP (30 µM) and siRNA (Scr and NRF2) while seeding. Cells were grown for 5 days in 
37°C and 5% CO2 humidified incubator. Images (5-10 images/flask) of each flask at 
different positions were taken using the Leica inverted phase-contrast microscope. Images 
were imported into ImageJ and approximately 100 cell borders were manually traced per 
treatment group. Areas of cells were measured using ImageJ and relative areas of the 
treatment groups were analyzed with GraphPad Prism 7 software. 
2.15. RNA sequencing (RNA-Seq) 
T25 flask were seeded with mouse primary prostate fibroblast (1 × 106) cells in the 
presence of 30 μM MnTE-2-PyP or an equal volume of PBS. The next day, cells were 
either sham irradiated or treated with 2 Gy of X-rays (Rad Source RS-2000). 24 hours 
after irradiation, cells were harvested and washed two times with 1X PBS. Total cellular 
RNA was isolated using Quick-RNA™ MiniPrep (Plus) kit of Zymo Research following the 
manufacture’s protocol after genomic DNA removal and DNase treatment. The 
concentration and quality of total RNA was measured by Infinite M200 Pro plate reader 
(Tecan). Total RNA having a 260/280 ratio ~2.0 was used for further experiments. Total 
RNA was sent to City of Hope, CA for RNA sequencing. Sample quality control was 




using Illumina Stranded RNA-seq library preparation protocol. Quality control of the 
sequencing library was ensured by Qubit. RNA sequencing was done by RNA-seq 
Ribozero stranded protocol, which removes ribosomal RNA to enhance the mRNA signal 
in HiSeq 2500 Fast mode SE50. 
2.16. Mitochondrial function assays with MitoPlates S-1 
We used Biolog’s MitoPlates S-1 (14105, Biolog) plates containing preloaded substrates 
to study the effects of substrates on mitochondrial function. P3158 cells were seeded in 
the presence of PBS or 30 μM MnTE-2-PyP. The next day, cells were exposed to 3 Gy 
radiation and then cultured for 5 days before collection. Plates were prewarmed to room 
temperature, and Saponin stock solution (24x, 2.4 mg/ml) was made before cell 
preparation. Assay mix was made according to protocol and 30 µl of assay mix was 
distributed in each well. Plates were incubated at 37° C for 1 hour to allow substrates to 
dissolve fully. We used P3158 cells after trypsinization and washing with PBS. Cell pellets 
were resuspended in 5 ml of 1x Biolog MAS and filtered through a 70-micron nylon filter. 
After cell counting, 20,000 cells per 30 µl were dispensed in each well. To record the rates 
of dye reduction in the wells, the MitoPlate without lid was loaded into the Infinite M200 
Pro plate reader (Tecan), set to read absorption at 590 nm every 15-minutes for 2 hours 
at 37º C. 
2.17. Oxidative stress TF activation profiling plate array 
We used Signosis’s oxidative stress transcription factor (TF) activation profiling plate array 
(FA-1005, Signosis) to assess the impact of hydrogen peroxide generation by MnTE-2-
PyP on the activity of 16 oxidative stress sensitive TFs. Nuclear extracts were made from 




According to the manufacture’s protocol, reagents for the experiment were prepared 
before starting and maintained at the instructed temperatures. We made 30 µl of TF DNA 
complex using 5 µg of nuclear extract from every sample with 15 µl TF binding buffer mix, 
3 µl TF Probe mix for oxidative stress and ddH2O. TF DNA complex were incubated at 
room temperature for 30 minutes. Free probes were separated from TF DNA complex and 
eluted according to the manufacturer’s protocol. The hybridization of the eluted probes 
with the hybridization plate was performed at 42º C for overnight. The captured DNA probe 
is further detected with streptavidin-HRP conjugate system after washing and incubation 
steps. Luminescence is measured 15 minutes after the addition of the substrate using the 
Infinite M200 Pro plate reader (Tecan), set integration time to 1 second. The activity of 
TFs is shown by the relative light units measured for every sample. 
2.18. Statistical analysis 
All statistical tests were performed using the GraphPad Prism 8 software. Differences 
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple 
comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes 
a significant and the symbol (ns) denotes a non-significant difference as compared to the 
control (PBS) group. Data were obtained from at least 3 independent experiments unless 




Chapter 3. Results 
3.1. MnTE-2-PyP treatment and radiation exposure-mediated changes in gene 
expression 
To understand the signaling pathways associated with fibroblast activation and formation 
of the myofibroblast phenotype, and the mechanisms associated with the prevention of 
prostate radiation-induced fibrosis, our laboratory performed RNA Sequencing (RNA-Seq) 
of mouse primary prostate fibroblast cells. Cells were pretreated with either PBS or 30 μM 
MnTE-2-PyP a day before radiation exposure (2 Gy) and then collected 24 hours later for 
RNA isolation. After performing RNA-Seq analysis, changes in several different fibrotic 
and non-fibrotic gene expression was observed (data not shown).  
To confirm and validate the gene expression changes from the RNA-Seq data, we 
performed RT-qPCR analysis of NQO1, GSTA4, FGF9, and FGF10 mRNA levels which 
could play a role in the fibrotic process. RNA-Seq data indicated NQO1, GSTA4, FGF9 
and FGF10 are among the top 20 genes upregulated by MnTE-2-PyP treatment. NADPH 
quinone dehydrogenase 1 (NQO1) is a cytoprotective protein involved in the detoxification 
of cells when under stress. Glutathione s-transferase alpha 4 (GSTA4), is involved in 
cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic 
compounds. Fibroblast growth factor 9 (FGF9) and fibroblast growth factor 10 (FGF10) 
are members of the fibroblast growth factor (FGF) family of proteins. FGF family members 
possess broad mitogenic and cell survival activities and are involved in a variety of 
biological processes, including embryonic development, cell growth, morphogenesis, 




RT-qPCR analysis of NQO1, GSTA4, FGF9, and FGF10 mRNA levels in human prostate 
fibroblast cells showed that MnTE-2-PyP upregulated NQO1 and FGF10 expression (Fig. 
4: A, D). Upon MnTE-2-PyP treatment, NQO1 levels increase by ~2.4-fold (Fig. 4: A), and 
FGF10 (Fig. 4: D) increases by ~2.8-fold in comparison to PBS treated samples. Radiation 
exposure does not cause a significant increase in NQO1 and FGF10 mRNA levels (Fig. 
4: A, D). Further, there was no significant increase in GSTA4 and FGF9 expression upon 








Figure 4. MnTE-2-PyP treatment and radiation exposure mediated changes in 
gene expression. (A) Relative NQO1 mRNA levels in P3158 cells. (B) Relative GSTA4 
mRNA levels in P3158 cells. (C) Relative FGF9 mRNA levels in P3158 cells. (D) 
Relative FGF10 mRNA levels in human primary prostate fibroblast (HPrF) cells. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005) 
denotes a significant and the symbol (ns) denotes a non significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 























3.2. MnTE-2-PyP treatment and radiation exposure-mediated changes in 
extracellular matrix gene expression 
The extracellular matrix (ECM) is a three-dimensional network of extracellular 
macromolecules, such as collagen, enzymes, and glycoproteins, which provide structural 
support to surrounding cells. Fibrotic tissue post-irradiation correlates with an increase in 
the ECM proteins that make the surrounding tissue stiffer and sometimes is associated 
with tissue scarring. Excessive deposition of ECM by myofibroblast cells leads to improper 
tissue functioning and is the cause for some of the side effects observed in prostate cancer 
patients following radiation therapy. The excessive ECM deposition builds up over long 
periods of time (months to years) upon myofibroblast cell formation. Therefore, the side 
effects of radiation therapy are often observed years after initial radiation exposure, and 
the side effects progressively worsen over time.  
To test the expression of these ECM proteins upon radiation exposure and MnTE-2-PyP 
treatment, we selected some of the ECM genes from our RNA-Seq data, which showed 
downregulation upon MnTE-2-PyP treatment and performed RT-qPCR analysis in human 
prostate fibroblast cells. ECM genes selected for RT-qPCR analysis included POSTN, 
VITRIN, COL3A1, COL1A2, COL1A1, COL5A1, and COL6A2. POSTN expression was 
significantly reduced with MnTE-2-PyP treatment, and the level of increase post-radiation 
exposure was lower due to MnTE-2-PyP treatment (Fig. 5: A). VITRIN expression was 
significantly higher post-radiation exposure and the MnTE-2-PyP treatment did not show 
a significant increase in comparison to the PBS treated group (Fig. 5: B). COL3A1 
expression was significantly lower in MnTE-2-PyP treated groups, with and without 
radiation exposure, in comparison to the PBS treated group (Fig. 5: C). COL1A2, COL1A1, 
COL5A1 and COL6A2 did not show a significant change either with radiation or MnTE-2-




expression of COL1A2, COL1A1, COL5A1 and COL6A2 may take a longer time upon 
MnTE-2-PyP treatment or require a higher radiation dose to fully observe significant 
differences. Overall, the data indicate that MnTE-2-PyP treatment may be involved in 
regulating signaling pathways leading to specific downregulation of certain ECM genes, 
POSTN, and COL3A1, after 1-2 days of MnTE-2-PyP treatment in human prostate 





Figure 5. MnTE-2-PyP treatment and radiation exposure mediated changes in 
extracellular matrix gene expression. (A) Relative POSTN mRNA levels in P3158 
cells. (B) Relative VITRIN mRNA in P3158 cells. (C) Relative COL3A1 mRNA levels in 
P3158 cells. (D) Relative COL1A2 mRNA levels in P3158 cells. (E) Relative COL1A1 
mRNA in P3158 cells. (F) Relative COL5A1 mRNA levels in P3158 cells. (G) Relative 
COL6A2 mRNA levels in P3158 cells. Differences were determined by using a 1-way 
ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol (*p 
< 0.05, **p < 0.005, ***p < 0.0005) denotes a significant and the symbol (ns) denotes 
a non significant difference as compared to the control (PBS) group. Data were 








3.3. MnTE-2-PyP treatment and radiation exposure mediated changes in gene 
expression in mouse primary prostate fibroblast cells 
We observed significant changes in gene expression of NQO1, POSTN, and COL3A1 in 
human prostate fibroblast cells (P3158). Therefore, we were interested in testing and 
confirming these results in mouse primary prostate fibroblast cells as we had only one 
replicate of RNA-Seq data from these cells. In mouse primary prostate fibroblast cells, we 
observed similar RT-qPCR results for NQO1, POSTN, and COL3A1 expression, as 
observed in human prostate fibroblast cells. MnTE-2-PyP caused a significant increase in 
NQO1 mRNA levels, and a significant decrease in POSTN and COL3A1 levels, when 






Figure 6. MnTE-2-PyP treatment and radiation exposure mediated changes in 
gene expression in mouse primary prostate fibroblast cells. (A) Relative NQO1 
mRNA levels. (B) Relative POSTN mRNA. (C) Relative COL3A1 mRNA levels. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005) 
denotes a significant and the symbol (ns) denotes a non-significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 












3.4. MnTE-2-PyP treatment and radiation exposure mediated changes COL3A1 
protein levels in human prostate fibroblast cells 
Collagen, type III, alpha 1 (COL3A1), is one of the fibrillar collagens and is found as a 
major structural component in hollow organs such as large blood vessels, uterus, and 
bowel. Since we observed a significant decrease in COL3A1 mRNA levels in both human 
and mouse prostate fibroblast cells, we wanted to determine if these results correlated 
with COL3A1 protein levels upon MnTE-2-PyP treatment. Further, we hypothesized that 
the increase in COL3A1 levels after radiation exposure would be much higher and 
accumulate over a more extended period. Immunoblotting results of human prostate 
fibroblast cells (P3158 cell) whole-cell lysate revealed that MnTE-2-PyP causes a 
significant decrease in COL3A1 protein levels (Fig. 7: A-B). Radiation exposure showed 
an early trend towards an increase in COL3A1 protein levels, and this was not a significant 
increase as we looked at the whole-cell lysate at 48 hours after radiation exposure. 
However, this data indicates that the change in mRNA levels observed after MnTE-2-PyP 





Figure 7. MnTE-2-PyP treatment and radiation exposure mediated changes 
COL3A1 protein levels in human prostate fibroblast cells. (A) Immunoblotting 
analysis of COL3A1 levels in P3158 Cells. (B) Quantification of COL3A1 levels in 
whole-cell lysate from immunoblot in panel A. Differences were determined by using a 
1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The 
symbol (*p < 0.05, **p < 0.005) denotes a significant and the symbol (ns) denotes a 
non-significant difference as compared to the control (PBS) group. Data were obtained 


































3.5. MnTE-2-PyP treatment and radiation exposure mediated changes in NRF2 
signaling pathway downstream targets in RNA-seq data 
In our RNA-seq data, we observed NQO1 to be one of the top 15 most significantly 
upregulated genes by MnTE-2-PyP and is a direct downstream target of NRF2 mediated 
transcriptional expression. Confirmation of an increase in NQO1 mRNA in mouse and 
human prostate fibroblast cells suggested that activation of the NRF2 pathway by MnTE-
2-PyP may be responsible for the upregulation of NQO1. To investigate the activation of 
the NRF2 signaling pathway, we first examined the expression levels of other NRF2 
downstream targets in the RNA-Seq data. There are several downstream targets of the 
NRF2 pathway; however, in mouse prostate fibroblast cells, we observed an increase in 
Nqo1, Gsta4, Cyp1b1, Gstm1, Mgst1, Il6, Gstt1, Ugt1a7c, Fth1, Smad6, Cav1, Fgf7, 
Gsta3, Gclc, Gclm, Hmox1 and Mgst3, in MnTE-2-PyP treated groups. This increase in 
downstream targets ranged from a ~1.4-fold to ~2.5-fold in comparison to the PBS treated 
group in our RNA-Seq data (Table 3). Increase in expression of genes such as Gsta4, 
Gstm1, Mgst1, Gstt1, Gsta3, Gclc, Gclm, and Mgst3, are known to contribute towards a 
reduction in overall hydrogen peroxide levels. Further, the RNA-Seq data indicated that 
radiation exposure did not cause an activation of the NRF2 pathway (Table 3). This 
signature of an increase in NRF2 pathway activation is also seen in the MnTE-2-PyP 
treated group exposed to radiation (2 Gy). Further, changes in some of the other 
transcriptional targets (fibrotic and non-fibrotic targets) seen in the RNA-Seq data maybe 







Table 3. MnTE-2-PyP treatment and radiation exposure mediated changes in 
NRF2 signaling pathway downstream targets in RNA-Seq data. (A) RNA-Seq data 
of NRF2 pathway downstream target genes upregulated (fold-change) by MnTE-2-PyP 




NRF2 downstream target genes upregulated upon T2E treatment 
Genes 
PBS T2E PBS T2E 
0 Gy 0 Gy 2 Gy 2 Gy 
Nqo1 1.0 2.5 -1.0 2.7 
Gsta4 1.0 2.5 -1.1 3.2 
Cyp1b1 1.0 2.4 -1.0 2.9 
Gstm1 1.0 2.1 1.1 2.3 
Mgst1 1.0 2.1 1.1 2.4 
Il6 1.0 2.0 1.2 2.4 
Gstt1 1.0 1.9 -1.0 1.9 
Ugt1a7c 1.0 1.9 1.1 2.1 
Fth1 1.0 1.8 1.0 2.3 
Smad6 1.0 1.7 -1.1 1.5 
Cav1 1.0 1.6 -1.0 1.3 
Fgf7 1.0 1.6 1.1 1.6 
Gsta3 1.0 1.6 1.1 1.7 
Gclc 1.0 1.5 1.1 1.8 
Gclm 1.0 1.5 1.0 1.4 
Hmox1 1.0 1.4 1.1 1.6 




3.6. MnTE-2-PyP treatment and radiation exposure mediated changes in levels of 
the NRF2 signaling pathway of prostate fibroblast cells 
The NRF2 signaling pathway is a critical antioxidant pathway that is involved in 
cytoprotection and radioprotection. There are several mechanisms through which the 
NRF2 pathway is regulated of which the canonical pathway involving KEAP1 and the non-
canonical pathway involving SQSTM1 are best established. Therefore, to test the 
activation of the NRF2 signaling pathway upon MnTE-2-PyP treatment, we performed 
immunoblotting experiments and identified changes in protein levels of NRF2, KEAP1, p-
SQSTM1, SQSTM1, and NQO1. KEAP1 is a negative regulator of NRF2 and is a 
cytoplasmic binding partner of NRF2. Changes in SQSTM1 and its phosphorylation is also 
reported to be involved in NRF2 pathway activation [212, 236]. 
Further, we tested if the changes in NQO1 mRNA levels correlate with the changes in 
NQO1 protein levels due to NRF2 pathway activation. In whole-cell lysates of prostate 
fibroblast cells (P3158 cells), a significant increase (~1.8-fold) in NRF2 levels in MnTE-2-
PyP treated groups with and without radiation was observed after five days (Fig. 8: A-B). 
We detected a decrease in KEAP1 levels, an increase in total SQSTM1 levels, and an 
increase in phosphorylation of SQSTM1 (Ser349) protein, which is involved in the 
canonical and non-canonical NRF2 signaling pathway activation mechanisms (Fig. 8: A). 
Correspondingly, NQO1 levels significantly increased with MnTE-2-PyP treatment (Fig. 8: 
A, C). This data indicates that MnTE-2-PyP is involved in NRF2 pathway activation 






Figure 8. MnTE-2-PyP treatment and radiation exposure mediated changes in 
levels of NRF2 signaling pathway of prostate fibroblast cells. (A) Immunoblotting 
analysis of whole-cell lysate for NRF2, KEAP1 (Canonical pathway), phospho-
SQSTM1 (Ser349, Non-canonical pathway), SQSTM1 and NQO1 from P3158 cells. 
(B) Quantification of NRF2 levels from immunoblot in panel A. (C) Quantification of 
NQO1 levels from immunoblot in panel A. Differences were determined by using a 1-
way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol 
(*p < 0.05, ***p < 0.0005) denotes a significant and the symbol (ns) denotes a non 
significant difference as compared to the control (PBS) group. Data were obtained from 























3.7. MnTE-2-PyP treatment dose required for NRF2 pathway activation 
To identify the minimum and maximum dose of MnTE-2-PyP required to activate the NRF2 
signaling pathway in vitro, we performed a MnTE-2-PyP treatment dose curve ranging 
from 0-30 µM (Fig. 9: A). We found that 48 hours of MnTE-2-PyP treatment caused a 
significant increase in NRF2 levels at 10 µM (~1.3-fold), with a maximum increase at 30 
µM (~1.7-fold, Fig. 9: A-B). NQO1 levels increased significantly at 5 µM (~1.5-fold), and a 
maximum increase in NQO1 was achieved at 30 µM (~1.8-fold) after 48 hours of MnTE-
2-PyP treatment (Fig. 9: A, C). SOD2, whose expression is in part controlled by the NRF2 
pathway, increased significantly at 2.5 µM (~1.5-fold) with a maximum increase at 30 µM 
(~2.3-fold, Fig. 9: A, D). However, there could be other signaling pathways or transcription 
factors being activated by MnTE-2-PyP treatment that contribute to a significant increase 
in SOD2 expression at low doses. To test the significance of NRF2 pathway activation in 
the prevention of radiation-induced fibrosis, we selected 30 µM as the MnTE-2-PyP 
treatment dose for our experiments because this dose produced the most robust activation 






Figure 9. MnTE-2-PyP treatment dose required for NRF2 pathway activation. (A) 
Immunoblotting analysis for NRF2, NQO1 and SOD2 levels in whole-cell lysate of 
P3158 cells treated with 2.5 μM, 5 μM, 10 μM, 20 μM and 30 μM MnTE-2-PyP for 48 
h. (B) Quantification of NRF2 levels from immunoblot in panel A. (C) Quantification of 
NQO1 levels from immunoblot in panel A. D. Quantification of SOD2 levels from 
immunoblot in panel A. Differences were determined by using a 1-way ANOVA followed 
by a post hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005, ***p < 
0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a non-
significant difference as compared to the control (PBS) group. Data were obtained from 























3.8. MnTE-2-PyP treatment time course analysis of NRF2 levels in the nucleus of 
prostate fibroblast cells 
NRF2 is a transcription factor, and its nuclear localization is required for transcriptional 
activity. After an increase in oxidative stress, NRF2 is released from KEAP1, which leads 
to its translocation into the nucleus, and increases gene expression of its downstream 
targets. The increase in NRF2 nuclear levels can be quick or slow depending on the 
mechanism of NRF2 pathway activation. To understand the process and confirm the 
activation of the NRF2 pathway by MnTE-2-PyP treatment, we looked at the time-
dependent increase in NRF2 levels in the nucleus. We observed a significant increase in 
the levels of NRF2 nuclear localization within 16 hours of MnTE-2-PyP treatment and a 
maximum level (~2.3-fold) of NRF2 within the nucleus at 48 hours (Fig. 10: A-B). NRF2 
levels are maintained for at least five days when MnTE-2-PyP is present in the culture 
media (Fig. 10: A-B). These results indicate that the NRF2 pathway is activated by MnTE-






Figure 10. MnTE-2-PyP treatment time course analysis of NRF2 levels in the 
nucleus of prostate fibroblast cells. (A) Time course analysis of NRF2 protein level 
in nuclear extract after MnTE-2-PyP treatment in P3158 cells. (B) Quantification of 
NRF2 levels in nuclear extract from immunoblot in panel A. Differences were 
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple 
comparisons. The symbol (*p < 0.05, ***p < 0.0005, ****p < 0.00005) denotes a 
significant and the symbol (ns) denotes a non-significant difference as compared to the 
control (PBS) group. Data were obtained from 3 independent experiments, bars in the 









3.9. MnTE-2-PyP treatment increases NRF2’s DNA binding activity  
Enzyme-linked immunosorbent assay (ELISA), is a plate-based assay technique designed 
for detecting relative levels of proteins and its ability to bind a given epitope (DNA or 
antigen) attached to the plate surface. To validate the activation of NRF2 signaling by 
MnTE-2-PyP and NRF2’s capacity to bind antioxidant response elements (ARE) DNA 
elements, we performed a NRF2 specific colorimetric ELISA assay containing the NRF2 
consensus binding site (5’ – GTCACAGTGACTCAGCAGAATCTG – 3’) immobilized onto 
a 96-well plate. Active Nrf2 present in the nuclear extract specifically binds to the 
oligonucleotide. In prostate fibroblast nuclear extracts (P3158 cells), we observed a ~1.5-
fold significant increase in NRF2 binding to ARE DNA elements in MnTE-2-PyP treated 
groups (Fig. 11: A). Importantly, radiation exposure, which is known to generate ROS and 
increase oxidative stress, did not lead to an activation of the NRF2 signaling pathway in 
the prostate fibroblast cells (Fig. 11: A). These results indicate that MnTE-2-PyP is a NRF2 






Figure 11. MnTE-2-PyP treatment increases NRF2’s DNA binding activity. (A) 
Quantification of NRF2 DNA binding activity measured using an ELISA for nuclear 
extracts from fibroblast cells at 5 days post-irradiation and 6 days post-MnTE-2-PyP 
treatment. Differences were determined by using a 1-way ANOVA followed by a post 
hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005) 
denotes a significant and the symbol (ns) denotes a non significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 









3.10. Nuclear extracts of prostate fibroblast have increased NRF2-DNA interaction 
upon MnTE-2-PyP treatment 
Electrophoretic mobility shift assay (EMSA) is an affinity electrophoresis technique used 
to study protein–DNA interactions. For visualization purposes, the nucleic acid fragment 
is usually labeled with a radioactive label (P32). An increase in NRF2 levels in the nucleus 
of fibroblast cells should lead to an increase in the amount of NRF2 binding to the 
radiolabeled oligonucleotides containing NRF2 DNA binding sequence. Therefore, we 
made nuclear extracts from prostate fibroblast cells (P3158) that were PBS or MnTE-2-
PyP treated ± radiation (5 Gy) exposed and collected five days later. Our results showed 
a significant increase in the size of the NRF2 band (lane 2 and lane 4) in samples treated 
with MnTE-2-PyP with or without radiation exposure in comparison to the PBS treated 
sample (lane 1, Fig. 12: A-B). We also observed a significant decrease in the NRF2 band 
in the samples exposed to radiation (lane 3) in comparison to the PBS treated sample 
(lane 1, Fig. 12: A-B). This data indicates that MnTE-2-PyP treatment causes an increase 
in NRF2 DNA binding activity and radiation exposure causes a decrease in NRF2 DNA 
binding activity. Therefore, radiation exposure does not activate the major antioxidant 







Figure 12. Nuclear extracts of prostate fibroblast have increased NRF2-DNA 
interaction upon MnTE-2-PyP treatment. (A) NRF2 DNA binding activity from 
nuclear extracts of P3158 cells determined by EMSA. (B) Quantification of NRF2 
binding band in panel A. Differences were determined by using a 1-way ANOVA 
followed by a post hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005, 
***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a 
non significant difference as compared to the control (PBS) group. Data were obtained 









3.11. Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2-PyP 
treatment 
To understand the mechanism of the NRF2 signaling pathway activation by MnTE-2-PyP, 
and the reason for an increase in NRF2 protein levels in prostate fibroblast cells, we first 
checked for changes in NRF2 and NQO1 mRNA levels with a MnTE-2-PyP treatment time 
course. A significant increase in NQO1 mRNA can be observed at 24 hours (~1.4-fold), 
48 hours (~1.7-fold) and 72 hours (~2.5-fold) of MnTE-2-PyP treatment due to activation 
of the NRF2 signaling pathway (Fig. 13: A). However, activation of the NRF2 pathway and 
an increase in NRF2 protein levels by MnTE-2-PyP treatment is not associated with an 
increase in NRF2 mRNA levels (Fig. 13: B). Therefore, changes in NRF2 protein levels by 
MnTE-2-PyP is probably associated with a post-transcriptional mechanism of activation 






Figure 13. Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2-
PyP treatment. (A) Relative NQO1 mRNA levels in P3158 cells. (B) Relative NRF2 
mRNA levels in P3158 cells. Differences were determined by using a 1-way ANOVA 
followed by a post hoc Tukey’s test for multiple comparisons. The symbol (*p < 0.05, 
**p < 0.005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a non 
significant difference as compared to the control (PBS) group. Data were obtained from 









3.12. MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes 
changes in SQSTM1 (non-canonical) 
To understand the mechanism of NRF2 pathway activation by MnTE-2-PyP treatment, we 
investigated changes in the canonical NRF2 signaling pathway involving KEAP1 and non-
canonical NRF2 signaling pathway involving SQSTM1 Ser349 phosphorylation. We 
performed immunoblotting time course experiments with MnTE-2-PyP treatment and 
looked at the changes in NRF2, KEAP1, SQSTM1, p-SQSTM1 (Ser349) and NQO1 levels. 
An increase in NRF2 levels upon MnTE-2-PyP treatment showed significant differences 
at the 24 hour time point (Fig. 14: A-B). KEAP1 levels begin to significantly decrease 
(~0.49-fold) at the 6 hour time point and reach a maximum decrease around the 48 hour 
time point (~0.36-fold) (Fig. 14: A, C). Whereas, a significant increase in SQSTM1 levels 
and phosphorylation of SQSTM1 (Ser349) begin around the 48 hour time point (Fig. 14: 
A, D-E). Thereby, indicating that changes in the canonical NRF2 signaling pathway 








Figure 14. MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes 
changes in SQSTM1 (non-canonical). (A) Immunoblotting time course analysis of 
NRF2, KEAP1, SQSTM1, phospho-SQSTM1 (p-SQSTM1 Ser349), and NQO1 protein 
level after MnTE-2-PyP treatment of P3158 cells. (B) Quantification of NRF2 levels 
from immunoblot in panel A. (C) Quantification of KEAP1 levels from immunoblot in 
panel A. (D) Quantification of SQSTM1 levels from immunoblot in panel A. (E) 
Quantification of p-SQSTM1/SQSTM1 levels from immunoblot in panel A. Differences 
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for 
multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 
0.00005) denotes a significant and the symbol (ns) denotes a non-significant difference 
as compared to the control (PBS) group. Data for figures in panel A-C were obtained 









3.13. Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE-2-PyP 
To test if SQSTM1 is involved in NRF2 activation in human prostate fibroblast cells upon 
MnTE-2-PyP treatment, we downregulated SQSTM1 and immunoblotted for NRF2, NQO1 
and KEAP1. We also downregulated NRF2 and NQO1 using siRNA molecules in the same 
experiment to serve as controls. We observed that the knockdown of SQSTM1 did not 
prevent the activation of NRF2 by MnTE-2-PyP (lane 3-4, Fig. 15: A). Further, knockdown 
of NRF2 prevented an increase in SQSTM1 levels upon MnTE-2-PyP treatment (lane 5-
6, Fig. 15: A). The knockdown of NQO1 did not prevent changes in either NRF2 or 
SQSTM1 levels caused by MnTE-2-PyP treatment (lane 7-8, Fig. 15: A). This data 
indicates that changes in SQSTM1 are a downstream consequence of activation of the 







Figure 15. Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE-
2-PyP. (A) Immunoblotting results of Scrambled siRNA (Scr), SQSTM1 siRNA 
(Sqstm1), NRF2 siRNA (Nrf2) and Nqo1 (siRNA) treated with or without MnTE-2-PyP 
(4 days). Relative quantification of each protein band is enumerated below each 









3.14. MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1 knockout 
mouse embryonic fibroblast cells 
To confirm the role of KEAP1 in the activation of the NRF2 signaling pathway by MnTE-
2-PyP treatment, we used KEAP1 knockout and wild-type mouse embryonic fibroblast 
cells. In KEAP1 knockout cells, we did not observe an increase in nuclear NRF2 levels 
(lane 3-4, Fig. 16: A) or an increase in NQO1 levels caused by MnTE-2-PyP treatment 
(lane 7-8, Fig. 16: A). Further, the increase in SOD2 levels caused by MnTE-2-PyP 
treatment was partially prevented in KEAP1 knockout cells (lane 5-8, Fig. 16: A). This data 







Figure 16. MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1 
knockout mouse embryonic fibroblast cells. (A) Immunoblotting analysis of nuclear 
and cytoplasmic extracts from wild type (W.T.) and KEAP1 knockout (K.O.) mouse 
embryonic fibroblast cells treated with MnTE-2-PyP for 5 days. Relative quantification 
of each protein band is enumerated below each immunoblot. Data in panel A are 









3.15. MnTE-2-PyP treatment leads to an increase in hydrogen peroxide levels 
MnTE-2-PyP, a superoxide scavenger, converts superoxide molecules to hydrogen 
peroxide. We hypothesized that hydrogen peroxide generated by MnTE-2-PyP could play 
a role in NRF2 pathway activation. To understand and quantify the changes in hydrogen 
peroxide upon MnTE-2-PyP treatment, we used the ROS-GLO H2O2 assay. We observed 
a significant increase in hydrogen peroxide levels within 3 hours of MnTE-2-PyP treatment 
in human prostate fibroblast cells (Fig. 17: A). A maximum increase in hydrogen peroxide 
levels can be observed at the 6 hour time point of MnTE-2-PyP treatment (Fig. 17: A). 
Beyond the 6-hour time point, the hydrogen peroxide levels are significantly higher but 
reduced, likely due to the activation of the NRF2 signaling pathway, which leads to an 
increase in the expression of hydrogen peroxide scavenging enzymes or a decrease in 
cell proliferation upon MnTE-2-PyP treatment. This data indicates that the increase in 
hydrogen peroxide caused by MnTE-2-PyP treatment may be responsible for the 








Figure 17. MnTE-2-PyP treatment leads to an increase in hydrogen peroxide 
levels. (A) Hydrogen peroxide generation by MnTE-2-PyP treatment over time in HPrF 
cells, measured by ROS-GLO H2O2 assay. Differences were determined by using a 1-
way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol 
(**p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) 
denotes a non-significant difference as compared to the control (PBS) group. Data 












3.16. Hydrogen peroxide treatment activates the NRF2 signaling pathway 
Hydrogen peroxide can act as a signaling molecule, which can lead to either activation or 
inhibition of signaling pathways that contain redox-sensitive thiols [195]. To further 
understand the mechanism of NRF2 signaling pathway activation by MnTE-2-PyP, we 
treated human primary fibroblast (HPrF) cells with hydrogen peroxide. We used HPrF cells 
as they are more sensitive to changes in signaling pathways and serve as an additional 
cell type to confirm NRF2 pathway activation. We treated HPrF cells with 25 µM, 50 µM, 
and 100 µM of hydrogen peroxide every 24 hours for four consecutive days. With 
increasing doses of hydrogen peroxide, we observed a ~1.7-2.9-fold significant increase 
in NRF2 levels (Fig. 18: A-B). We also observed significant increases in NQO1 (~2.5-fold) 
and SOD2 (~2.8) levels with the addition of hydrogen peroxide at the highest dose (100 
µM, Fig. 18: A, C-D). This indicates that the conversion of superoxide to hydrogen 








Figure 18. Hydrogen peroxide treatment activates the NRF2 signaling pathway. 
(A) Immunoblotting analysis of NRF2, NQO1 and SOD2 expression in HPrF cells 
treated with hydrogen peroxide (25 μM, 50 μM, and 100 μM) every day for 4 
consecutive days. (B) Quantification of NRF2 levels from immunoblot in panel A. (C) 
Quantification of NQO1 levels from immunoblot in panel A. (D) Quantification of SOD2 
levels from immunoblot in panel A. Differences were determined by using a 1-way 
ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol (**p 
< 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) 
denotes a non-significant difference as compared to the control (PBS) group. Data 










3.17. Removal of hydrogen peroxide using N-acetyl cysteine (NAC) treatment 
prevents NRF2 pathway activation by MnTE-2-PyP treatment 
To remove hydrogen peroxide from cells and test its role in the activation of the NRF2 
pathway in prostate fibroblast cells, we used N-acetyl cysteine (NAC), which is a precursor 
for glutathione production (hydrogen peroxide scavenger). We pretreated HPrF cells with 
NAC for two days with a 12-hour replenishment cycle and then treated with MnTE-2PyP 
for three days and measured changes in the NRF2 pathway. We observed that a dose-
dependent NAC (1 mM and 2 mM) treatment caused a decrease in NRF2 levels (~0.5-
fold), and MnTE-2-PyP failed to significantly increase NRF2 levels upon NAC treatment 
(Fig. 19: A-B). Further, we observed that there was no significant increase in either NQO1 
or SOD2 levels in NAC + MnTE-2-PyP treated groups (Fig. 19: A, C-D), indicating that the 
hydrogen peroxide generated by MnTE-2-PyP is likely playing a role in NRF2 pathway 








Figure 19. Removal of hydrogen peroxide using N-acetyl cysteine (NAC) 
treatment prevents NRF2 pathway activation by MnTE-2-PyP treatment. (A) 
Immunoblotting analysis of HPrF cells pretreated for 2 days (every 12 hours) with NAC 
(1 mM and 2 mM) followed by MnTE-2-PyP treatment for 3 days. (B) Quantification of 
NRF2 levels from immunoblot in panel A. (C) Quantification of NQO1 levels from 
immunoblot in panel A. (D) Quantification of SOD2 levels from immunoblot in panel A. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005) denotes a significant 
and the symbol (ns) denotes a non-significant difference as compared to the control 
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures 









3.18. MnTE-2-PyP treatment increased NAD+ and NADH levels 
An increase in NRF2 signaling and the downstream target NQO1 can lead to significant 
changes in cellular metabolites. NQO1 is an enzyme that is involved in the conversion of 
quinones to hydroquinones and utilizes NADH for this conversion [237, 238]. Thus, when 
NQO1 detoxifies quinones, it produces NAD+ [239, 240], which is also a cofactor for the 
activity of sirtuin enzymes that play a significant role in cellular protection through the 
regulation of acetylation of histones and non-histone proteins [237, 239-243]. Therefore, 
we measured the levels of NAD+ and NADH after MnTE-2-PyP treatment in prostate 
fibroblast cells (P3158). We found a significant ~2-fold increase in NAD+ and NADH levels 
(Fig. 20: A, B). The ratio of NAD+/NADH did not change significantly; this is an indicator 
that the redox health of the cells post MnTE-2-PyP treatment is maintained (Fig. 20: C). 
Similarly, in primary human prostate fibroblast (HPrF) cells, we observed a significant 
increase in NAD+ and NADH levels after MnTE-2-PyP treatment and radiation exposure 
(Fig. 20: D, E). In HPrF cells, the ratio of NAD+/NADH showed a significant decrease in 
the samples exposed to radiation, and MnTE-2-PyP treatment prevented this decrease in 
NAD+/NADH ratio in comparison to the PBS treated group (Fig. 20: F). This data indicates 
that changes in the NRF2 signaling pathway due to MnTE-2-PyP treatment can impact 







Figure 20. MnTE-2-PyP treatment increased NAD+ and NADH levels. P3158 cells 
and HPrF cells were pretreated with MnTE-2-PyP for 24 hours and then analyzed 48 
hours post-irradiation. (A) Relative NAD+ levels in P3158 cells. (B) Relative NADH 
levels in P3158 cells. (C) Relative ratios of NAD+/NADH levels in P3158 cells. (D) 
Relative NAD+ levels in HPrF cells. (E) Relative NADH levels in HPrF cells. (F) Relative 
ratios of NAD+/NADH levels in HPrF cells. Differences were determined by using a 1-
way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol 
(*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the 
symbol (ns) denotes a non-significant difference as compared to the control (PBS) 
group. Data were obtained from 3 independent experiments, bars in the figures 









3.19. MnTE-2-PyP treatment increased the activity of sirtuin family proteins in 
nuclear and mitochondrial extracts 
To further understand the impact of an increase in NAD+ levels by MnTE-2-PyP treatment 
on the activity of radioprotective enzymes, we measured the activity of the sirtuin family of 
proteins that use NAD+ as a cofactor for its activity. Sirtuins are a class of proteins that 
possess deacetylase activity or mono-ribosyltransferase activity and are associated with 
epigenetic remodeling, cellular protection, radiation protection, sugar metabolism, and cell 
cycle regulation [243, 244]. Sirtuins localized in different subcellular organelles, such as 
the nucleus and mitochondria, play an important role in the development of RIF [56, 244]. 
Therefore, we measured sirtuin activity in nuclear extracts and found a ~1.4-1.8-fold 
increase in sirtuin activity in MnTE-2-PyP treated groups (Fig. 21: A). Radiation exposure 
also led to a ~1.4-fold increase in sirtuin activity. However, maximum change (~1.8-fold) 
in nuclear sirtuin activity was observed in MnTE-2-PyP treated group exposed to radiation 
(Fig. 21: A). In mitochondrial extracts, we observed a significant ~1.5-fold increase in 
sirtuin activity in the MnTE-2-PyP treated groups (Fig. 21: B). There was no significant 
increase in mitochondrial sirtuin activity after radiation exposure, which may be a reason 
for an increase in mitochondrial damage and a rise in mitochondrial ROS levels post-
irradiation [245-247]. This data indicates that MnTE-2-PyP treatment causes an increase 








Figure 21. MnTE-2-PyP treatment increased the activity of sirtuin family proteins 
in nuclear and mitochondrial extracts. (A) Relative sirtuin activity in nuclear extracts 
of P3158 cells. (B) Relative sirtuin activity in mitochondrial extracts of P3158 cells. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p 
< 0.00005) denotes a significant and the symbol (ns) denotes a non-significant 
difference as compared to the control (PBS) group. Data were obtained from 3 









3.20. MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation (Ac-
K122) and SOD2 activity 
Since we observed an increase in mitochondrial sirtuin activity after MnTE-2-PyP 
treatment, we investigated the acetylation status of mitochondrial proteins. SOD2, is a 
downstream target of SIRT3 (mitochondrial sirtuin). SIRT3 is known to directly deacetylate 
SOD2, which is the primary mitochondrial superoxide scavenging enzyme, and its 
acetylation status influences its activity. Therefore, we investigated the acetylation of 
SOD2 at K68 and K122 residues that can affect SOD activity [248-250]. SOD2 K68 
acetylation directs its homotetramer complex formation [251], and SOD2 K122 
deacetylation increases its catalytic activity by maintaining the positive charge of the 
electrostatic funnel that directs the movement of superoxide molecules to the active site 
of SOD2 [252]. Further, SOD2 expression is controlled by NRF2 activity, and we have 
observed a ~1.5-fold significant increase in SOD2 levels in MnTE-2-PyP treated groups 
(Fig. 22: A-B). We did not observe a significant increase in SIRT3 levels in MnTE-2-PyP 
treated groups (Fig. 22: A, C). However, MnTE-2-PyP treatment decreased SOD2 
acetylation at K122 residue (~0.41-fold) but did not change acetylation at K68 in 
comparison to PBS treated group normalized to total SOD2 levels (Fig. 22: A, D-E). We 
also observed a 1.52-fold significant increase in SOD2 K122 acetylation after radiation 
exposure, which was not observed in MnTE-2-PyP + radiated group (Fig. 22: A, E). This 
decrease in acetylation of SOD2 at K122 residue also correlated with a ~1.5-fold 
significant increase in SOD2 activity using an in-gel assay (Fig. 22: A, F). An increase in 
SOD2 activity can also be attributed to an increase in total SOD2 protein levels in 
comparison to PBS treated groups. Since SOD2 is a mitochondrial protein, we isolated 
the mitochondria from P3158 cells and measured SOD activity by a more sensitive 




activity in mitochondrial extracts of MnTE-2-PyP treated groups (Fig. 22: G). Notably, this 
increase in mitochondrial SOD activity could be responsible for the long-term indirect 
superoxide scavenging capacity induced by MnTE-2-PyP. Further, this increase in 
superoxide scavenging capacity in the mitochondria by SOD2 can be crucial in 








Figure 22. MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation 
(Ac-K122) and SOD2 activity. P3158 cells were pretreated with MnTE-2-PyP for 24 
hours and then analyzed 4 days post-irradiation exposure (5 Gy). (A) Immunoblotting 
analysis of NRF2, NQO1, total SOD2, SIRT3, SOD2 Ac-K68, SOD2 Ac-K122, and in-
gel SOD2 activity assay from whole-cell lysate. (B) Quantification of total SOD2 levels 
from immunoblot in panel A. (C) Quantification of SIRT3 levels from immunoblot in 
panel A. (D) Quantification of SOD2 acetylation at K68 to total SOD2 levels from 
immunoblot in panel A. (E) Quantification of SOD2 acetylation at K122 to total SOD2 
levels from immunoblot in panel A. (F) Quantification of SOD2 activity by in-gel assay 
shown in panel A. (G) Quantification of SOD activity (% inhibition rate) in the 
mitochondrial extracts using the xanthine oxidase - SOD activity assay. Differences 
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for 
multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005) denotes a 
significant and the symbol (ns) denotes a non-significant difference as compared to the 
control (PBS) group. Data were obtained from 3 independent experiments, bars in the 










3.21. NRF2 downregulation increases α-SMA levels (myofibroblast marker) which 
is partially rescued by MnTE-2-PyP treatment 
Radiation-induced fibrosis develops due to the transformation of fibroblasts to 
myofibroblasts, which are also known as activated fibroblasts. Identification and inhibition 
of pathways responsible for this transformation can prevent the development of fibrosis. 
An active NRF2 pathway prevents fibroblast transformation due to a reduction in the levels 
of ROS and the inhibition of the TGF-β signaling pathway, which is a known pro-fibrotic 
pathway. Further, we hypothesized that enhanced NRF2 signaling activity upon MnTE-2-
PyP treatment assists in maintaining normal fibroblast phenotype. HPrF cell are more 
sensitive to fibroblast to myofibroblast transformation in comparison to the immortalized 
prostate fibroblast cells (P3158). Therefore, we investigated the formation of the 
myofibroblast phenotype using HPrF cells. To study the role of ROS-mediated 
myofibroblasts formation, we seeded HPrF cells in the presence of NRF2 siRNA and 
MnTE-2-PyP treatment at the same time (day 0). After five days of treatment, cells were 
collected and analyzed for myofibroblast phenotype by measuring alpha-smooth muscle 
actin (α-SMA) levels, changes in cell size, and collagen contraction (Fig. 23-25). Further, 
we looked at differences in superoxide and total reactive oxygen species levels (Fig. 26). 
NRF2 protein is maintained at homeostatic levels by the binding of NRF2 to KEAP1 for 
immediate adaptive cellular responses in the face of a changing microenvironment. The 
use of NRF2 siRNA in experiments does not affect the NRF2 protein levels immediately, 
and it requires 48-72 hours for NRF2 protein to be fully reduced. Whereas, MnTE-2-PyP 
treatment effects the NRF2-KEAP1 system within the 48 hours of treatment. Therefore, 
the addition of NRF2 siRNA and MnTE-2-PyP at the same starting time point can still lead 
to partial NRF2 signaling pathway activation. In immunoblotting experiments setup 




NRF2 knockdown was achieved in the group treated with NRF2 siRNA and MnTE-2-PyP 
in comparison to the NRF2 siRNA treated group (Fig. 23: B). This also led to a partial 
expression of NQO1 in the NRF2 siRNA + MnTE-2-PyP treatment group (Fig. 23: B). α-
SMA levels, a marker for myofibroblast phenotype, increased by ~2.5-fold, when we 
compared the NRF2 siRNA + PBS treated group to the Scr siRNA + PBS treated group 
(Fig. 23: B, C). We observed a ~2.0-fold significant increase in α-SMA levels in the NRF2 
siRNA + MnTE-2-PyP treated group when compared to Scr siRNA + PBS treated group, 
likely due to the partial loss of NRF2 in the NRF2 siRNA + MnTE-2-PyP treated group 
(Fig. 23: B, C). However, the α-SMA levels in the NRF2 siRNA + MnTE-2-PyP treatment 
group were significantly lower than the NRF2 siRNA + PBS treatment group (Fig. 23: B, 
C). This indicated that a partial rescue in myofibroblast phenotype could be achieved due 







Figure 23. NRF2 downregulation increases α-SMA levels (myofibroblast marker) 
which is partially rescued by MnTE-2-PyP treatment. (A) Experimental timeline for 
siRNA treatment (Scrambled-Scr and NRF2 siRNA) and MnTE-2-PyP treatment. (B) 
Immunoblotting analysis of NRF2, NQO1, and α-SMA expression. (C) Quantification of 
α-SMA levels (myofibroblast marker) from immunoblot in panel B. Differences were 
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple 
comparisons. The symbol (**p < 0.005, ****p < 0.00005) denotes a significant and the 
symbol (ns) denotes a non-significant difference as compared to the control (PBS) 
group. Data were obtained from 3 independent experiments, bars in the figures 









3.22. NRF2 downregulation increases cell size, which is rescued by MnTE-2-PyP 
treatment due to partial NRF2 activation 
Activated fibroblasts or myofibroblasts are larger in size as compared to normal 
fibroblasts. In the same experimental setup and timeline as in (Fig. 24: A), we measured 
changes in cell size to determine the myofibroblast phenotype. NRF2 knockdown caused 
a ~3-fold significant increase in cell size, which was significantly reduced by MnTE-2-PyP 
treatment to ~1.4-fold a significant increase in the NRF2 knockdown group (Fig. 24: A-B). 
This indicates that MnTE-2-PyP can prevent changes in cell size or myofibroblast 








Figure 24. NRF2 downregulation increases cell size, which is rescued by MnTE-
2-PyP treatment due to partial NRF2 activation. (A) Representative images of 
changes in cell morphology (HPrF cells) from Scr siRNA, NRF2 siRNA and MnTE-2-
PyP treated groups. Scale bar: 250 μm. (B) Quantification of cell size by measuring the 
area of each cell after tracing cell boundary using ImageJ. Differences were determined 
by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. 
The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant 
and the symbol (ns) denotes a non-significant difference as compared to the control 
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures 











3.23. NRF2 downregulation activates fibroblast cells, which is rescued by MnTE-
2-PyP treatment due to partial NRF2 activation 
To further measure the myofibroblast phenotype, the most widely accepted technique is 
the collagen contraction assay, where the ability of cells to contract collagen discs is 
measured. The increase in contractility by myofibroblast cells is due to an increase in the 
expression of α-SMA. Upon NRF2 knockdown by siRNA, a significant (p=0.0004) increase 
in collagen contraction was observed in the PBS treated group (Fig. 25: A-B). In the MnTE-
2-PyP treated group, with partial NRF2 knockdown, the collagen contraction is prevented 
in comparison to the NRF2 knockdown + PBS treated group (Fig. 25: A-B). This data 
indicates that an active NRF2 pathway is essential to prevent the formation of 







Figure 25. NRF2 downregulation activates fibroblast cells, which is rescued by 
MnTE-2-PyP treatment due to partial NRF2 activation. (A) Representative collagen 
contraction assay to measure activation of fibroblast cells (HPrF cells) from Scr siRNA, 
NRF2 siRNA and MnTE-2-PyP treated groups. (B) Quantification of collagen disc area 
from panel A as measured using ImageJ. Differences were determined by using a 1-
way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol 
(*p < 0.05, ***p < 0.0005) denotes a significant and the symbol (ns) denotes a non-
significant difference as compared to the control (PBS) group. Data were obtained from 









3.24. NRF2 downregulation increases superoxide and total ROS levels, and MnTE-
2-PyP treatment reduces superoxide and total ROS levels in HPrF cells 
The NRF2 signaling pathway is the major antioxidant pathway in different cell types. Loss 
of the NRF2 pathway can lead to an increase in reactive oxygen species (ROS) that can 
drive fibroblast to myofibroblast transformation. Therefore, we investigated the changes in 
superoxide and total ROS levels by DHE assay. In the same experimental setup and 
timeline, as shown in Fig. 23: A, the highest levels of superoxide (1.50-fold) and total ROS 
(1.45-fold) were found in the NRF2 knockdown group treated with PBS (Fig. 26: A). In 
MnTE-2-PyP treated group, both superoxide and total ROS were significantly reduced 
(Fig. 26: A). In MnTE-2-PyP treated group with NRF2 knockdown, the superoxide and total 
ROS were significantly lower than the corresponding PBS treated NRF2 knockdown group 
due partial NRF2 activity (Fig. 26: B). This indicates that MnTE-2-PyP likely scavenges 







Figure 26. NRF2 downregulation increases superoxide and total ROS levels, and 
MnTE-2-PyP treatment reduces superoxide and total ROS levels in HPrF cells. 
(A) DHE assay used to measure superoxide levels by flow cytometric analysis (405 
nm). (B) DHE assay used to measure total ROS by flow cytometric analysis (488 nm). 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005, ****p < 0.00005) 
denotes a significant and the symbol (ns) denotes a non-significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 




















3.25. MnTE-2-PyP cannot prevent an increase in the α-SMA levels post-irradiation 
in the absence of the NRF2 pathway 
To investigate the role of NRF2 in the context of radiation exposure (3 Gy) and to achieve 
a complete NRF2 knockdown in MnTE-2PyP treated groups, we changed the 
experimental timeline for siRNA treatment and MnTE-2-PyP treatment as shown in (Fig. 
27: A). We seeded the cells with siRNA, and after two days, we treated the cells with 
MnTE-2-PyP, to eliminate any NRF2 protein that could be activated post-translationally by 
MnTE-2-PyP treatment. After 6 hours of MnTE-2-PyP treatment, we exposed the cells to 
radiation and performed immunoblotting on day 5 to confirm changes in NRF2 levels and 
its downstream target, NQO1 (Fig. 27: B-C). There was a significant increase in NRF2 
levels in the scrambled siRNA groups treated with MnTE-2-PyP but there was no 
significant increase in NRF2 levels in NRF2 siRNA groups treated with MnTE-2-PyP (Fig. 
27: B-C). In line with this, NQO1 levels were increased in scrambled siRNA groups treated 
with MnTE-2-PyP and completely lost in all NRF2 siRNA groups (Fig. 27: B). A significant 
increase in α-SMA levels were observed in scrambled siRNA treated, radiation-exposed 
PBS group, and all the NRF2 knockdown groups (Fig. 27: B, D). The maximum increase 
in α-SMA levels (>2-fold) can be observed in the NRF2 knockdown groups (Fig. 27: B, D). 
MnTE-2-PyP treatment reduced α-SMA levels in the scrambled treated, radiation exposed 
group but failed to significantly reduce α-SMA levels in NRF2 knockdown groups (Fig. 27: 
B, D). This data indicates that MnTE-2-PyP cannot prevent the increase in α-SMA levels 







Figure 27. MnTE-2-PyP cannot prevent the increase in α-SMA levels post-
irradiation in the absence of NRF2 pathway. (A) Experimental timeline for siRNA 
treatment (Scr siRNA and NRF2 siRNA), MnTE-2-PyP treatment, and radiation 
exposure (3 Gy) in HPrF cells. (B) Immunoblotting analysis of NRF2, NQO1, and α-
SMA expression. (C) Quantification of NRF2 from panel B after siRNA mediated 
knockdown. (D) Quantification of α-SMA from panel B, a marker for myofibroblast cells. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (**p < 0.005, ****p < 0.00005) denotes a 
significant and the symbol (ns) denotes a non-significant difference as compared to the 
control (PBS) group. Data were obtained from 3 independent experiments, bars in the 









3.26. MnTE-2-PyP treatment cannot prevent myofibroblast formation post-
irradiation in the absence of the NRF2 pathway 
To further measure the myofibroblast phenotype, we performed the collagen contraction 
assay with the experimental timeline shown in Fig. 27: A. MnTE-2-PyP prevents increase 
in α-SMA levels and the contraction of collagen discs in the scrambled treated + radiation 
exposed group, but failed to significantly rescue myofibroblast formation in the NRF2 
knockdown groups (Fig. 28: A-B). This indicates that the NRF2 pathway is essential to 
prevent myofibroblast formation and that MnTE-2-PyP prevents radiation-induced 










Figure 28. MnTE-2-PyP treatment cannot prevent myofibroblast formation post-
irradiation in the absence of NRF2 pathway. (A) Representative collagen contraction 
assay to measure myofibroblast phenotype formation after siRNA treatment (Scr siRNA 
and NRF2 siRNA), MnTE-2-PyP treatment, and radiation exposure (3 Gy) in HPrF cells. 
(B) Quantification of collagen disc area from panel A measured using ImageJ. 
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s 
test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005, ****p < 0.00005) 
denotes a significant and the symbol (ns) denotes a non-significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 









3.27. Prostate fibroblasts from NRF2-/- mice do not undergo transformation to 
myofibroblasts post-irradiation 
NRF2-/- mice have been shown to be sensitive and resistant to radiation damage 
depending on the tissue under investigation. Therefore, to test the role of NRF2 pathway 
activation by MnTE-2-PyP in prostate tissue, we isolated primary mouse prostate 
fibroblast (MPF) cells from Nfe2l2tm1Ywk (NRF2) knockout mice (C57BL/6J) obtained from 
The Jackson Laboratory. We cultured these cells ex vivo to investigate the role of MnTE-
2-PyP in radioprotection. We noticed that these fibroblasts were slower growing, were 
dependent on cell-cell contact for survival, and more challenging to culture in vitro in 
comparison to wild type primary mouse prostate fibroblast cells. Upon subjecting the 
NRF2-/- MPF cells to 24 hours of MnTE-2-PyP treatment and 2 Gy radiation exposure, no 
stark visual changes in cellular morphology can be observed at day five post-irradiation 
(data not shown). The collagen contraction assay showed no differences in irradiated cells 
with or without MnTE-2-PyP treatment (Fig. 29: A-B). Therefore, the NRF2-/- MPF cells 
appear to be activated without radiation exposure, and the role of MnTE-2-PyP in 









Figure 29. Prostate fibroblasts from NRF2-/- mice do not undergo transformation 
to myofibroblasts post-irradiation. (A) Representative collagen contraction assay to 
measure fibroblast activation isolated from NRF2-/- (NRF2 knockout) mice, exposed to 
MnTE-2-PyP treatment and radiation exposure (2 Gy). (B) Quantification of collagen 
disc area from panel A as measured by using ImageJ. Differences were determined by 
using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. 
The symbol (ns) denotes a non-significant difference as compared to the control (PBS) 
group. Data were obtained from 3 independent experiments, bars in the figures 









3.28. Mitochondrial function assayed by measuring the flow of electrons into the 
electron transport chain, post-irradiation, and MnTE-2-PyP treatment 
Mitochondria are vital energy-producing cellular organelles that are damaged due to 
radiation exposure and contribute to the increase in ROS, which drives fibroblast to 
myofibroblast transformation. MnTE-2-PyP could protect the mitochondria from radiation 
damage and can improve mitochondrial functioning due to the removal of superoxide and 
the activation of the NRF2 signaling pathway. To test mitochondrial functioning post-
irradiation and MnTE-2-PyP treatment, we used Biolog’s Mitoplate S1 assay that has 30 
preloaded substrates used by the mitochondria in 96 well plates. Mitochondrial function is 
assayed by measuring the rates of electron flow into and through the electron transport 
chain (ETC) from metabolic substrates that produce NAD(P)H or FADH2 such as L-malate, 
succinate, and pyruvate. Each substrate follows a different route, using different 
transporters to enter the mitochondria and different dehydrogenases to produce NAD(P)H 
or FADH2, The electrons travel from the beginning (1 or 2) to the distal portion of the 
electron transport chain where a tetrazolium redox dye acts as a terminal electron 
acceptor that turns purple upon reduction. 
We used human prostate fibroblast (P3158) cells, exposed to radiation (3 Gy) ± PBS or 
MnTE-2-PyP treatment, to study mitochondrial functioning. Upon radiation exposure, in 
the absence of any of the 30 substrates, there is an increase in the NAD(P)H/FADH2 
production leading to an increase in electron flow into and through the ETC in comparison 
to the PBS treated samples (Fig. 30: A). There is no significant difference between the 
PBS + radiation treated samples and the MnTE-2-PyP + radiation treated samples (Fig. 
30: A). Significant differences were observed in the PBS + radiation treated samples and 
the MnTE-2-PyP + radiation treated samples, when incubated with Pyruvic acid (Fig. 30: 




Tryptamine (Fig. 30: AA) and L-Ornithine (Fig. 30: AC). There was no significant difference 
between the PBS + radiation treated samples and the MnTE-2-PyP + radiation treated 
samples, when incubated with α-D-Glucose (Fig. 30: B), D-Glucose-6-PO4 (Fig. 30: C), D-
Gluconate-6-PO4 (Fig. 30: D), Alanyl-Glutamine (Fig. 30: E), Glycogen (Fig. 30: F), D-
Glucose-1-PO4 (Fig. 30: G), D,L-α-Glycerol-PO4 (Fig. 30: H), L-Lactic acid (Fig. 30: J), 
Citric acid (Fig. 30: K), cis-Aconitic acid (Fig. 30: L), α-Keto-Glutaric acid (Fig. 30: N), L-
Glutamic acid (Fig. 30: O), L-Malic acid (Fig. 30: R), γ-Amino-Butyric acid (Fig. 30: S), D,L-
β- Hydroxy-Butyric acid (Fig. 30: T), α-Keto-Butyric acid (Fig. 30: U), Acetyl-L-Carnitine 
(Fig. 30: V), Palmitoyl-D,L-Carnitine (Fig. 30: W), Octanoyl-L-Carnitine (Fig. 30: X), L-
Leucine (Fig. 30: Y), α-Keto-Isocaproic Acid (Fig. 30: Z) and L-Serine (Fig. 30: AB). 
Further, there is no significant difference in Pyruvic acid (Fig. 30: I), D,L-Iscocitric acid 
(Fig. 30: M), Succinic acid (Fig. 30: P), Fumaric acid (Fig. 30: Q), α-Keto-Glutaric acid (Fig. 
30: N) and L-Malic acid (Fig. 30: R) utilization when we compare the PBS treated sample 
to the MnTE-2-PyP + radiation treated sample. First, this data indicates MnTE-2-PyP 
treatment could be involved in protecting the mitochondria against radiation damage, 
thereby reducing its dependence on or consumption of these substrates (Pyruvic acid, D, 
L-Iscocitric acid, α-Keto-Glutaric acid, Succinic acid, Fumaric acid, L-Malic acid, 
Tryptamine, and L-Ornithine). Second, reduction in utilization of these substrates upon 
MnTE-2-PyP treatment could be an indicator of enhanced activity of the enzymes involved 
in cellular or mitochondrial metabolism. We think MnTE-2-PyP treatment could be 
effecting glycolysis (Pyruvic acid), citric acid cycle or Krebs cycle (Pyruvic acid, D, L-
Iscocitric acid, α-Keto-Glutaric acid, Succinic acid, Fumaric acid, L-Malic acid), tryptamine 
metabolism (Tryptamine) and urea cycle or ornithine cycle (L-Ornithine). Conversely, 
radiation exposure leads to an increase in the utilization of mitochondrial substrates to 





Figure 30. Mitochondrial function assayed by measuring the flow of electrons 
into the electron transport chain, post-radiation and MnTE-2-PyP treatment. 
P3158 cells were exposed to radiation (3 Gy) and pretreated with MnTE-2-PyP. Data 
collected at the 120 min after addition of cells to each well. Relative electron flow in the 
presence of (A) No substrate (Control), (B) α-D-Glucose, (C) D-Glucose-6-PO4, (D) D-
Gluconate-6-PO4, (E) Alanyl-Glutamine, (F) Glycogen, (G) D-Glucose-1-PO4, (H) D,L-
α-Glycerol-PO4, (I) Pyruvic Acid, (J) L-Lactic Acid, (K) Citric Acid, (L) cis-Aconitic Acid, 
(M) D,L-Isocitric Acid, (N) α-Keto-Glutaric Acid, (O) L-Glutamic Acid, (P) Succinic Acid, 
(Q) Fumaric Acid, (R) L-Malic Acid, (S) γ-Amino-Butyric Acid, (T) D,L-β- Hydroxy-
Butyric Acid, (U) α-Keto-Butyric Acid, (V) Acetyl-L-Carnitine, (W) Palmitoyl-D,L-
Carnitine, (X) Octanoyl-L-Carnitine, (Y) L-Leucine, (Z) α-Keto-Isocaproic Acid, (AA) 
Tryptamine, (AB) L-Serine, and (AC) L-Ornithine. Differences were determined by 
using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. 
The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant 
and the symbol (ns) denotes a non significant difference as compared to the control 
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures 




















3.29. Time dependent, MnTE-2-PyP mediated activation of 16 oxidative stress 
related transcription factors 
Hydrogen peroxide is a ROS that is less reactive than superoxide but can still oxidize and 
cause changes in signaling pathways through post-translational modifications of cysteine 
residues. We know that MnTE-2-PyP converts superoxide to hydrogen peroxide, which 
leads to activation of the NRF2 signaling pathway in prostate fibroblast cell. However, we 
do not know the effect of MnTE-2-PyP on other oxidative stress sensitive transcription 
factors that may be activated along with NRF2. To study the changes in other transcription 
factors, we used Signosis’s oxidative stress TF activation profiling plate array, that 
measures changes in 16 oxidative stress related TFs, including AP1, ATF4, CBF/NFY, 
EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53, SMAD, SRF, and STAT3. 
We treated human prostate fibroblast cells (P3158) with MnTE-2-PyP for 0, 4, 8, 16, 24, 
and 48 hours to understand time dependent changes in the nuclear activity of the above 
TFs. We observed that 48 hours of MnTE-2-PyP treatment causes an increase in activity 
by ~1.5-fold or more in IRF, FOXO1, NFAT, NRF2, P53, HSF, SRF, STAT3, ATF4, NFkB 
and SMAD (Fig. 31: A). This data indicates that MnTE-2-PyP treatment leads to activation 
of other TFs at the 48-hour time point, which can be responsible for changes in some of 







Figure 31. Time dependent, MnTE-2-PyP mediated activation of 16 oxidative 
stress related transcription factors. (A) Relative transcription factor activity of AP1, 
ATF4, CBF/NFY, EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53, 
SMAD, SRF, and STAT3 over 0, 4, 8, 16, 24, and 48 hours of MnTE-2-PyP treatment 









3.30. Time dependent, radiation mediated activation of 16 oxidative stress related 
transcription factors 
We know that radiation exposure can lead to an increase in superoxide levels and other 
ROS species. However, we are unsure of this increase in superoxide, and other ROS 
species can activate oxidative stress sensitive transcription factors in prostate fibroblast 
cells. To understand this process and better study the mechanisms of radioprotection, we 
exposed human prostate fibroblast (P3158) cells to 3 Gy radiation and collected the 
samples at 0, 1, 4, 8, 12, and 16 hours post-irradiation time points. Our results indicate, at 
the 1 hour post-radiation time point, there was ~1.5-fold or more activation in IRF, NRF2, 
STAT3 and ATF4 transcription factors (Fig. 32: B). NRF2 and SMAD activity also peaked 
around the 12 hours post-radiation time point (Fig. 32: B). Further, the activity of TFs such 
as FOXO1, HIF, CBF/NFY, HSF, SRF, STAT3, ATF4, NFkB, and SMAD show a decrease 
in activity at the 8 hours post-radiation time point (Fig. 32: B). Overall, this data indicates 
that radiation exposure does not lead to a substantial increase in the activity of oxidative 







Figure 32. Time dependent, radiation mediated activation of 16 oxidative stress 
related transcription factors. (A) Relative transcription factor activity of AP1, ATF4, 
CBF/NFY, EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53, SMAD, 
SRF, and STAT3 over 0, 1, 4, 8, 12, and 16 hours post-irradiation in nuclear extracts 









3.31. MnTE-2-PyP treatment and radiation exposure mediated changes in NQO1 
mRNA in PC3 cells 
Since activation of the NRF2 pathway by MnTE-2-PyP is involved in radioprotection in 
normal human prostate fibroblast cells. We were investigated if MnTE-2-PyP activates 
NRF2 signaling in prostate cancer cells. In PC3 (prostate cancer cell line) cells, MnTE-2-
PyP does not lead to a significant increase in NQO1 mRNA (Fig. 33: A), which is a NRF2 
downstream target. Therefore, MnTE-2-PyP may not be involved in the radioprotection of 







Figure 33. MnTE-2-PyP treatment and radiation exposure mediated changes in 
NQO1 mRNA in PC3 cells. (A) Relative NQO1 mRNA levels in PC3 cells. Differences 
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for 
multiple comparisons. The symbol (ns) denotes a non-significant difference as 
compared to the control (PBS) group. Data were obtained from 3 independent 








3.32. MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling  
MnTE-2-PyP’s analog molecule, MnTnBuOE-2-PyP (BuOE) is currently in clinical trials for 
glioblastoma, head and neck cancer, and anal cancer as a radioprotector. MnTnBuOE-2-
PyP is a more lipophilic compound because of its extended alkyl chain and is used at a 
much lower dose in comparison to MnTE-2-PyP to achieve radioprotection. Therefore, we 
tested if MnTnBuOE-2-PyP can activate the NRF2 signaling pathway like MnTE-2-PyP at 
a dose lower than 5 μM. Further, we tested if these compounds activate NRF2 signaling 
in mouse myoblast cells C2C12 cells to understand its application in other tissue types for 
other applications. Immunoblotting results showed an increase in NRF2 protein levels at 
1.0 μM dose of MnTnBuOE-2-PyP treatment and 15 μM of MnTE-2-PyP treatment (Fig. 
34: A-B). Similarly, a significant difference in expression of NQO1 was achieved at 1.0 μM 
dose of MnTnBuOE-2-PyP treatment and 15 μM of MnTE-2-PyP treatment in C2C12 cell 
line (Fig. 34: A). NOX4 showed a trend towards a decrease in expression, and SOD2 
showed a trend towards an increase in expression with 1.0 μM dose of MnTnBuOE-2-PyP 
treatment and 15 μM of MnTE-2-PyP treatment (Fig. 34: A). This indicates that both MnTE-
2-PyP and MnTnBuOE-2-PyP are activators of the NRF2 signaling pathway in different 







Figure 34. MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling. 
(A) Immunoblotting analysis of whole-cell lysate of C2C12 cells treated with 
MnTnBuOE-2-PyP (BuOE) at 0.5 μM, 1.0 μM and MnTE-2-PyP at 15 μM for 96 hours. 
(B) Quantification of NQO1 levels from immunoblot in panel A. Differences were 
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple 
comparisons. The symbol (*p < 0.05, ***p < 0.0005) denotes a significant and the 
symbol (ns) denotes a non-significant difference as compared to the control (PBS) 
group. Data were obtained from 3 independent experiments, bars in the figures 



















Chapter 4. Conclusion and discussion 
4.1. Significance of the NRF2 pathway activation in maintaining human health…. 
Several studies have reported that an active NRF2 pathway is involved in maintaining 
human health and proper cellular functioning [254, 255]. NRF2 knockout mice are viable 
and fertile, but show lower reproductive performance, reduced immobility, decreased 
antioxidant reserve capacity and are extremely vulnerable to various toxic insults. This is 
because NRF2 controls the expression of a battery of genes involved in various cellular 
functions. The NRF2 pathway regulates oxidative stress, cellular metabolism, DNA repair, 
drug transport, inflammation, and cross-talks with other signaling pathways.  
The NRF2 pathway is the master regulator of oxidative stress in most cell types and is 
involved in maintaining redox balance [209, 256]. It has been reported to control the 
expression of all three SODs and other antioxidant proteins such as NQO1, glutathione s-
transferase (GST), catalase (CAT), thioredoxin (TRX), glutathione peroxidase (GPx), and 
glutathione-disulfide reductase (GSR) through direct and indirect mechanisms. Levels of 
superoxide and hydrogen peroxide are noticeably decreased upon the expression of the 
NRF2 downstream targets. Superoxide generated by radiation exposure is one of the main 
drivers for the development of RIF because studies involving the addition of SOD proteins 
and SOD mimics protect from radiation damage. Mice treated with SOD1 show a decrease 
in radiation-induced intestinal inflammation and upregulation of intercellular adhesion 
molecule-1 (ICAM-1), which is involved in pro-inflammatory signaling [257]. SOD2 
overexpression protects fibroblast cells from transformation induced by radiation [258-
260]. Similarly, SOD3 overexpression prevents an increase in the activation of the TGFβ-




In addition to superoxide removal through the downstream targets of the NRF2 pathway, 
there are metabolic processes that contribute towards radioprotection. The NRF2 
signaling pathway is directly involved in regulating drug metabolism, DNA repair, purine 
metabolism, pentose metabolism, lipid metabolism, inflammation, and proteostasis.  
NRF2 metabolic processes are regulated through the >242 NRF2 downstream 
transcriptional targets that contain NRF2 binding sites and through the protein-protein 
interactions of NRF2 [210, 262]. The NRF2 metabolic network inhibits lipogenesis, 
supports beta-oxidation of fatty acids, facilitates flux through the pentose phosphate 
pathway, increases NADPH regeneration and purine biosynthesis, which are essential 
processes for replacing damaged macromolecules after radiation exposure. The NRF2 
pathway impacts cellular bioenergetics by regulating the availability of mitochondrial 
substrates required for respiration [263]. Absence of NRF2, lowers mitochondrial NADH 
levels and ATP production due to inhibition of oxidative phosphorylation [263, 264]. To 
compensate for a decrease in ATP production in NRF2 knockout cells, cells activate 
glycolytic pathways. This highlights the importance of NRF2 in mitochondrial metabolism 
and functioning [263]. Further, NRF2 regulates DNA repair by controlling the expression 
of the enzyme 8-oxoguanine DNA glycosylase, which is involved in DNA base excision 
repair [265, 266]. The NRF2 pathway is also involved in DNA double strand break repair 
through its interaction with BRCA1 and regulation of 53BP1 expression [267].  
In addition to radioprotection, the NRF2 pathway plays a significant role in the influx-efflux 
of drugs and the metabolism of drugs. This regulation is carried out by several transporters 
and metabolic enzymes that are downstream targets of the NRF2 pathway [268, 269]. We 
also envision that when used in combination with toxic chemotherapy drugs, manganese 




activation of the NRF2 pathway in normal tissues, which will be discussed in future 
directions.  
As mentioned in the introduction, the NRF2 pathway crosstalks with the TGF-β signaling 
pathway, which is the most widely reported pro-fibrotic pathway [226, 227, 270]. The 
crosstalk between the NRF2 pathway and TGF-β pathway is responsible for the 
expression of the fibrotic markers and ECM proteins, which can also lead to epithelial-
mesenchymal transitions and the formation of myofibroblast cells [271].  
Inflammation plays a major role in the formation of myofibroblasts and the development of 
RIF. The NRF2 pathway is known to crosstalk with the NF-κB pathway, which is a pro-
inflammatory pathway [272]. NRF2 deficiency has been reported to increase NF-κB 
activity, increase macrophage and neutrophil infiltration, increase serum levels of pro-
inflammatory cytokines such as interleukin 6 (IL6), C-C Motif Chemokine Ligand 2 (CCL2), 
interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin 12B (IL 
12B), which contribute to radiation-induced injury [270, 272, 273]. NRF2 deficiency results 
in an increase in ROS levels, which induce NFKB inhibitor alpha (IκBα) phosphorylation 
and subsequent degradation, which leads to the activation of the NF-κB pathway [274]. 
Further, heme oxygenase 1 (HMOX1 or HO-1), a downstream target of the NRF2 pathway 
can also inhibit the NF-κB pathway [272, 275, 276]. Conversely, activation of the NF-κB 
pathway can inhibit the NRF2 pathway by depriving the CREB binding protein (CREBBP) 
of the NRF2 transcription site and facilitating the recruitment of histone deacetylase 3 




4.2. Mechanism of NRF2 pathway activation by manganese porphyrin 
compounds 
There are several mechanisms through which the NRF2 signaling pathway can be 
activated. Our findings indicate that MnTE-2-PyP is a post-translational activator of the 
NRF2 signaling pathway as we observed no change in NRF2 mRNA levels but did observe 
a significant increase in NRF2 protein levels. Since manganese porphyrin compounds 
convert superoxide to hydrogen peroxide, and the removal of hydrogen peroxide through 
NAC treatment prevents NRF2 pathway activation in prostate fibroblast cells, we suspect 
that hydrogen peroxide is causing NRF2 pathway activation through post-translational 
modifications. In a recent study, an imbalance in superoxide-hydrogen peroxide levels 
caused by paraquat (increases superoxide) and porphyrin exposure (SOD2-like molecule) 
has been reported to be involved in NRF2 activation in keratinocytes [278]. Further, 
MnTBAP, a SOD mimetic, has been reported to be an NRF2 activator in rat-
cardiomyoblasts [279]. Therefore, MnTE-2-PyP can activate the NRF2 pathway due to the 
conversion of superoxide to hydrogen peroxide.  
KEAP1 is a well-known inhibitor of NRF2 signaling that maintains homeostatic levels of 
NRF2. KEAP1 binds DLG and ETH motifs of NRF2, which favors CUL3-mediated 
ubiquitination of NRF2 and subsequent proteasome degradation [280, 281]. Hydrogen 
peroxide, which is generated by manganese porphyrin compounds [168], is known to 
cause oxidative modification and/or S-glutathionylation (in the presence of glutathione) of 
cysteine residues of redox-sensitive proteins [167, 168, 177, 185, 206, 282, 283]. We have 
shown that hydrogen peroxide levels increase 6 hours after MnTE-2-PyP treatment and 
KEAP1 levels decrease around the 6 hour time point in prostate fibroblast cells. Therefore, 
MnTE-2-PyP likely activates the NRF2 pathway due to oxidative modifications or post-




Alternative mechanisms of NRF2 pathway activation by manganese porphyrin compounds 
could involve changes in NRF2 phosphorylation at Ser-40 by protein kinase C (PKC), 
mitogen-activated protein kinase 14 (MAPK14 or p38), extracellular-signal-regulated 
kinase (ERK), PI3K/AKT, and changes in ubiquitination/proteasomal degradation [212, 
284, 285]. An increase in NRF2 phosphorylation by glycogen synthase kinase 3 beta 
(GSK3B) can decrease its nuclear accumulation [286]. Further, NRF2 cysteine residues 
(Cys235, Cys311, Cys316, Cys414, and Cys506) can undergo electrophilic modification or post-
translational modifications similar to those seen on KEAP1 [287]. To further understand 
these mechanisms of NRF2 pathway activation, we plan to perform mass spectrometry 
experiments after MnTE-2-PyP treatment and measure the post-translational 
modifications of the NRF2 pathway proteins. 
4.3. The mechanism by which MnTE-2-PyP prevents myofibroblast formation 
Radiation-induced fibrosis (RIF) is caused by the transformation of fibroblasts to 
myofibroblasts. This transformation of fibroblasts is driven by ROS generated after 
radiation exposure [6]. Superoxide levels increase immediately after radiation exposure 
and native SOD enzymes convert some of this superoxide to hydrogen peroxide. 
However, this is not enough to prevent fibroblast transformation. The addition of MnTE-2-
PyP boosts the cellular capacity to convert superoxide to hydrogen peroxide through direct 
and indirect mechanisms, which is sufficient to prevent the development of RIF. However, 
we do not completely understand the mechanism of KEAP1 oxidation or other 
modifications caused by the hydrogen peroxide generated by manganese porphyrin 
compounds. Further, the location of the hydrogen peroxide generated by manganese 




Two essential NRF2 downstream targets involved in cellular protection against radiation 
exposure are NQO1 and SOD2. NQO1 serves as a cytoprotective and metabolic protein 
that generates NAD+, which serves as a cofactor to increase the activity of the sirtuin family 
of proteins [239, 240, 288]. We have confirmed an increase in cellular NAD+ levels and an 
increase in sirtuin activity within nuclear and mitochondrial extracts. In addition to the 
increase in SOD2 expression caused by NRF2 pathway activation, mitochondrial sirtuin 
proteins can deacetylate SOD2 to increase its enzymatic activity and further enhance 
mitochondrial superoxide scavenging capacity, likely due to an increase in NAD+ levels. 
This could lead to a long-term increase in superoxide scavenging capacity and improved 
mitochondrial health due to manganese porphyrin treatment. 
The inner mitochondrial membrane is impermeable to NADH and NAD+. However, the 
electrons from NADH can be carried by either the glycerol 3-phosphate shuttle or the 
malate-aspartate shuttle to regenerate the NADH within the mitochondria [289-291]. We 
acknowledge that the changes in NAD+ levels after MnTE-2-PyP treatment and the NRF2 
pathway activation may be independent of changes in NQO1 levels. They could be 
associated directly with changes in mitochondrial health, number, and activity, or other 
NRF2 downstream targets [292, 293]. However, the role of NAD+ in increasing sirtuin 
activity and cellular protection is well known [237, 240, 241, 288, 294-296]. 
NAD+ precursor nicotinamide, has been shown to prevent endothelial-to-mesenchymal 
transition induced by TGF-β [297] and renal fibrosis by suppressing inflammation [298]. 
Further, targeting NAD+ metabolism in cancer enhances its radiosensitivity [299].  
The increase in activity of sirtuin proteins has been shown to be involved in radioprotection 
through the use of compounds such as resveratrol [300] and polydatin [132]. Sirtuin 
proteins are also known to exert antifibrotic effects [301], delay aging, and regulate 




nonalcoholic fatty liver disease [244]. We have previously reviewed the role of each of the 
sirtuin proteins and their targets in RIF [39]. However, we still need to investigate the 
acetylation status of targets other than SOD2 that could play a role in the prevention of 
RIF after MnTE-2-PyP treatment. 
Through knockdown experiments of NRF2, we confirmed that NRF2 is essential to prevent 
prostate fibroblast to myofibroblast transformation, and MnTE-2-PyP fails to prevent this 
transformation in the absence of NRF2 upon irradiation. Further, the NRF2 pathway is 
also known to inhibit the TGF-β signaling pathway, a known pro-fibrotic pathway that 
controls the expression of several extracellular matrix proteins and α-SMA expression, 
which has been discussed in the previous section [226, 227]. Previously, our laboratory 
has confirmed that MnTE-2-PyP inhibits TGF-β1-mediated fibroblast activation and 




































Figure 35. The mechanism by which MnTE-2-PyP prevents 
myofibroblast formation. Exposure to radiation generates superoxide 
in fibroblasts leading to transformation to myofibroblasts. MnTE-2-PyP 
treatment coverts this superoxide to hydrogen peroxide, which can 
oxidize redox sensitive proteins. KEAP1 is a redox sensitive protein that 
can be oxidized by hydrogen peroxide. Oxidized KEAP1 dissociates from 
NRF2 (inactive state) in the cytoplasm and can lead to a reduction in 
KEAP1 levels. NRF2 upon dissociation (active state) translocates to the 
nucleus to bind ARE elements in the promoter region of genes such as 
NQO1 and SOD2. An increase in NQO1 causes metabolic changes that 
can lead to an increase in NAD+ that serve as a cofactor for the sirtuin 
(SIRT) family of proteins. We have observed an increase in sirtuin activity 
in the mitochondria that also correlates with deacetylation of SOD2 
(K122) protein. An increase in SOD2 expression and deacetylation by 
mitochondrial sirtuin proteins leads to enhancement in SOD2 activity, 
further augmenting superoxide scavenging capacity upon MnTE-2-PyP 
treatment. Therefore, we observe a significant decrease in superoxide 
levels in fibroblast cells, which prevents its transformation to 
myofibroblasts. Our laboratory has previously observed inhibition of the 
TGF-β1/SMAD signaling pathway that is responsible for the α-SMA 
expression by MnTE-2-PyP treatment [1]. Based on other studies, we 
speculate that this occurs due to the crosstalk of the NRF2 signaling 

















4.4. Reduction of POSTN and COL3A1 in fibroblasts by MnTE-2-PyP 
We have shown MnTE-2-PyP to downregulates periostin (POSTN), which is also known 
as osteoblast-specific factor 2, in mouse and human prostate fibroblast cells. We suspect 
MnTE-2-PyP downregulates POSTN expression due to NRF2 pathway activation as it has 
been reported to be one of the downstream targets [225, 302, 303]. POSTN, is a 
component of the ECM involved in regulating intercellular adhesion and plays a key role 
during development and wound repair [304]. POSTN contributes to proper collagen 
function and is predominantly expressed in collagen-rich tissues such as the skin [305]. 
High expression of POSTN correlates with the development of a fibrotic phenotype in 
several tissues [302, 306-312]. It is known to promote myofibroblast formation and type 1 
collagen production through TGF-β activation [310, 313-316]. The mechanism of POSTN-
induced activation of TGF-β involves an increase in the activity of matrix metallopeptidase 
2 (MMP2) and matrix metallopeptidase 9 (MMP9) [313]. Loss of POSTN ameliorates 
adipose tissue fibrosis and inflammation due to a reduction in macrophage recruitment 
[304, 317]. POSTN expression in fibrosis and inflammation is believed to be enhanced 
due to the secretion of interleukin 4 (IL4) and interleukin 13 (IL13) cytokines [315]. Further, 
POSTN is involved in progression of prostate [318-321], breast [322], lung [323], ovarian 
cancer [324], and nasopharyngeal cancer [318, 325]. POSTN interacts with multiple cell-
surface receptors, most notably integrins, and signals via the PI3K/AKT pathway to 
promote tumor aggressiveness [309, 318]. Therefore, reduction in POSTN by MnTE-2-
PyP is an important finding that could play a role in prevention of RIF and prostate cancer 




COL3A1 is one of the matrisome proteins whose expression is also regulated by NRF2 in 
fibroblasts [225, 326, 327]. We have observed that MnTE-2-PyP decreases COL3A1 
expression from human and mice prostate fibroblasts. An increase in COL3A1 expression 
correlates with the development of fibrosis and other fibrotic markers such as α-SMA, 
COL1A1, and fibronectin [326, 328-330]. Mutations in COL3A1 is known to disrupt the 
formation of ECM [328, 331]. An increase in oxidative stress results in impaired NEDD9 
proteolytic degradation, thereby increasing the formation of the neural precursor cell 
expressed, developmentally down-regulated 9 and NK2 Homeobox 5 (NEDD9-NKX2–5) 
complex that increases COL3A1 expression [330]. Therefore, we think that the reduction 
in oxidative stress by MnTE-2-PyP treatment or NRF2 pathway activation contributes 
towards the reduction in COL3A1, which is a marker for fibrosis. 
4.5. Applications of manganese porphyrin compounds as NRF2 activators in 
other disorders and diseases 
We have shown manganese porphyrins work as NRF2 activators that helps in 
radioprotection. Additionally, there are several other NRF2 activators that are either plant-
derived chemicals or synthetic chemicals that have demonstrated radioprotection and are 
being used for other chronic diseases. However, manganese porphyrins are more 
effective in activating the NRF2 pathway due to its catalytically active properties. We have 
observed a dose dependent increase in NRF2 pathway activation, and we can control the 
levels of NRF2 pathway activation by adapting the correct dosing strategies.  
NRF2 activators that are plant-derived phytochemicals include sulforaphane, curcumin, 
epigallocatechin-3-gallate, resveratrol, cafestol, kahweol, cinnamonyl-based compounds, 
zerumbone, garlic oganosulfur compounds, lycopene, and carnosol [332]. Synthetic 




dithiole-3-thione) and dimethyl fumarate (DMF), which is also known as BG-12 or 
Tecfidera (Oral formulation) [332]. Additionally, new NRF2 activator compounds such as 
2-trifluoromethyl-2’-methoxychalone, mitigates myelosuppression and radiation damage 
[333]. These compounds can be classified into different categories depending on the 
mechanism of NRF2 pathway activation; electrophilic compounds, non-electrophilic 
compounds or protein-protein interaction inhibitors, GSK-3 inhibitors, synoviolin 1 (SYVN1 
or HRD1) inhibitors (LS-102), p62 (SQSTM1) activator (rapamycin), and BTB domain and 
CNC homolog 1 (BACH1) inhibitor (HPP-4382) [334]. Electrophilic compounds that cause 
electrophilic modification of KEAP1 cysteine residues and include molecules such as 
bardoxolone-methyl, RTA-408, DMF, ALKS-8700, oltipraz, ursodiol, sulforaphane 
ITH12674, curcumin, resveratrol, and CXA-10. Non-electrophilic compounds or protein-
protein interaction inhibitors, which interfere in NRF2-KEAP1 interaction, include peptides, 
1,2,3,4-tetrahydroisoquinoline core, benzenesulfonyl-pyrimidone, 1,4-
diaminonaphthalene core, sulfonyl coumarins and arylcyclohexyl pyrazoles. GSK-3 
inhibitors include tideglusib, nordihydroguaiaretic acid, terameprocol and enzastaurin 
[334]. Based on our findings manganese porphyrin compounds likely belong to the 
category of electrophilic compounds that cause NRF2 activation through KEAP1 
modification.  
NRF2 activator drugs are under clinical development for a plethora of chronic disorders 
and diseases that require restoring of redox balance, resolution of inflammation, and 
normalizing mitochondrial metabolism [211, 281, 334]. NRF2 activators also function as 
chemopreventive and chemoprotective molecules. Conversely, NRF2 inhibitor drugs have 
demonstrated to have anticancer properties for tumors that have a hyperactive NRF2 
pathway [334]. To date, the most successful NRF2 activator is fumaric acid ester dimethyl 




2013 for multiple sclerosis [335]. Other NRF2 activator drugs are currently in different 
phases of clinical trials for their application in diabetes, kidney disease, liver disease, 
lymphoid malignancies, Alport syndrome, pulmonary hypertension, mitochondrial 
myopathy, Friedreich’s ataxia, inflammation, cancer, psoriasis, rheumatoid arthritis, 
schistosomiasis, nonalcoholic steatohepatitis, nonalcoholic fatty liver, chronic hepatitis C, 
cholelithiasis, diarrhea and pulmonary arterial hypertension [211]. 
Drugs such as resveratrol have been shown to decrease KEAP1 levels and activate NRF2 
signaling, similar to MnTE-2-PyP [336, 337]. Resveratrol has been used as a 
radioprotector in several publications for tissues other than the prostate (intestine, salivary 
gland, ovary, hematopoietic stem cells, skin, and lung) [135, 136, 139, 140, 338]. Further, 
resveratrol has also been shown to be an activator of sirtuin proteins [336]. Like MnTE-2-
PyP, resveratrol has been shown to scavenge superoxide molecules, directly and 
indirectly, however, the clinical application of resveratrol has been unsuccessful due to 
poor oral bioavailability (less than 5%), as it undergoes rapid metabolism and elimination 
[339, 340]. Resveratrol is not a catalytically active compound whereas, manganese 
porphyrin compounds are catalytically active and hence do not require high dose of 
treatment. The bioavailability of MnTE-2-PyP has been studied in different tissues [167], 
and its bioavailability can be enhanced by up to 120-fold by changing the alkyl chain, which 
modulates its lipophilicity [341]. Therefore, MnTE-2-PyP, as a superoxide scavenger, 
NRF2 activator, SOD2, and NQO1 enhancer, and a sirtuin activator would work as a 





4.6. Mechanisms associated with antitumor and radiosensitizing effects of 
manganese porphyrin compounds 
Manganese porphyrin compounds have demonstrated antitumor and radiosensitizing 
effects in prostate cancer and other cancers [342, 343]. This is mainly due to the 
differences in cellular networks and oxidative stress levels that are present between tumor 
and normal tissues. Manganese porphyrin compounds work as a prooxidant in some 
cancers and as an antioxidant in normal tissues post-radiation due to the differences in 
the intracellular microenvironment. The relative oxidative stress levels in normal tissue are 
much lower in comparison to the cancer cells of certain cancer types. Further, we think 
that the activity and expression of antioxidant enzymes have been maximized in certain 
cancers and, therefore, are more susceptible to cell death by the prooxidant effects of 
manganese porphyrin compounds.  
In prostate cancer, specifically in the PC3 cancer cell line, manganese porphyrins produce 
high levels of intracellular hydrogen peroxide (up to a 2-fold increase in the nucleus) [234]. 
This leads to oxidation of a chromatin-modifying protein, P300, which is a histone 
acetyltransferase (HAT) enzyme. This results in a decrease in affinity for P300 
transcriptional complex to the DNA and a change in the transcriptional profile of cancer 
cells. Further, a reduction in histone acetylation (H3K9Ac) at specific gene promoters (PAI-
1) can be observed. However, we have not observed an activation of the NRF2 pathway 
in the PC3 cell line. We think that the NRF2 pathway in these cancer cells (PC3) might be 
defective, thereby preventing its activation and increasing its susceptibility to radiation 
damage. Further, the level of hydrogen peroxide increase in these cells might be triggering 
cell death pathways and causing DNA damage before any activation of the NRF2 




peroxide generation by manganese porphyrin in prostate cancer cells and normal 
fibroblast cell is under investigation in our laboratory. 
Understanding the differential pathways and molecules in normal tissues versus prostate 
cancer altered by manganese porphyrin compounds will vastly improve the therapeutic 
application of manganese porphyrin compounds and is the biggest challenge in the field. 
The ability of native antioxidant enzymes that can scavenge hydrogen peroxide generated 
by manganese porphyrin compounds determines their role as radioprotective agents or 
radiation sensitizing agents. In our laboratory, we are investigating the oxidation of some 
of the proteins in prostate cancer, which would further explain the mechanism of antitumor 
and radiosensitizing effects of manganese porphyrin compounds. 
4.7. Future directions 
We have shown that MnTE-2-PyP protects from radiation-induced myofibroblast formation 
through the activation of NRF2 signaling by knockdown experiments. However, radiation 
had no effect on the activation of NRF2-/- primary mice prostate fibroblast cells ex vivo. It 
is possible that these prostate fibroblast cells isolated from NRF2-/- mice already have a 
myofibroblast phenotype due the stress of handling the cells that prevents its activation 
post-irradiation. We also observed that these NRF2-/- prostate fibroblast cells are more 
difficult to culture in vitro and do not proliferate as well as the wild-type prostate fibroblast 
cell. It is possible that they might be more senescent and thereby preventing their 
activation post-irradiation. It has been shown that the intestinal crypts of NRF2-/- mice are 
radiation-resistant [223]. Therefore, for future studies the best model to study the role of 
NRF2 in radioprotection of the prostate after MnTE-2-PyP treatment would be to develop 




We are currently investigating radioprotection mediated by the NRF2 pathway using wild-
type and NRF2-/- mice, exposed to radiation ± MnTE-2-PyP. We have begun scoring for 
the visible symptoms of radiation damage after pelvic radiation exposure. Mice were 
exposed to a total of 35 Gy, which was fractionated over five days at 7 Gy each day. We 
evaluated radiation damage every week and scored the mice for hair loss, sores, tucked 
leg, redness or inflammation, and a prolapsed penis (Appendix A, Fig. 36). This ongoing 
experiment will be continued for a total of 4 months to measure changes in chronic 
radiation-induced damage. At the end of 4 months, different pelvic tissues (Prostate, 
colon, bladder, and skin) will be collected to investigate the formation of myofibroblasts 
and fibrosis. We suspect that the NRF2-/- mice may show a more severe fibrotic phenotype 
upon radiation exposure in comparison to the wild-type mice. This experiment would also 
help us determine the role of manganese porphyrin compounds in preventing 
myofibroblast formation in vivo due to direct ROS scavenging.  
For our future studies, we would also like to explore the growth of prostate cancer in NRF2-
/- mice versus wild-type mice. The results of this experiment would determine if the 
activation of NRF2 by MnTE-2-PyP in normal tissue would have an impact on prostate 
cancer growth. Alternatively, we can isolate prostate fibroblast cells from NRF2-/- mice and 
wild-type mice and co-culture these fibroblast cells with prostate cancer cells and assess 
the proliferation of cancer cells.  
In vivo studies of the development of RIF in the presence of tumor cells still need to be 
performed. Tumor cells develop a microenvironment that is different from that seen in 
normal tissues without tumor. The fibroblast cells associated with the cancer are referred 
to as cancer-associated fibroblasts (CAFs). CAFs have a phenotype that is different from 
the normal fibroblasts. Their phenotype resembles more of an activated fibroblast or 




that understanding changes in CAFs upon radiation exposure ± MnTE-2-PyP treatment 
and its impact on the tumor cells would be one of the future directions of the project. We 
think that MnTE-2-PyP treatment may inhibit some of the secretory molecules from the 
CAFs, such as POSTN, which would impact prostate tumor growth. 
We have confirmed NRF2 pathway activation by manganese porphyrin compounds in 
different cell lines in our in vitro experiments. However, we still need to confirm NRF2 
pathway activation in mice treated with the drug. Preliminary results of mice treated with 
MnTE-2-PyP show a likely activation of the NRF2 pathway after two months of treatment 
in wild-type C57BL/6J mice obtained from The Jackson Laboratory (Appendix B, Fig. 37). 
In prostate and liver tissue, we see a trend towards the upregulation of NQO1 mRNA. A 
similar trend was observed in NQO1 protein levels in skin and liver tissues by 
immunoblotting. Bladder and colon tissue do not show a trend in the upregulation of NQO1 
mRNA. We suspect that only certain cell types, such as fibroblast cells, might have an 
activation of the NRF2 pathway upon MnTE-2-PyP treatment in some of these tissues. 
The heterogeneous tissue lysate samples analyzed might not be the best indicator for 
NRF2 pathway activation by MnTE-2-PyP treatment in vivo. Further, our results may be 
significant only if we examine the different cell types in these tissues separately. In an 
acute, 2 week experiment of PBS and MnTE-2-PyP treatment, of wild-type C57BL/6J mice 
obtained from the Charles River Laboratory, we did not see a trend towards an increase 
in NRF2, NQO1 or SOD2 protein levels in kidney, liver, prostate and skin tissue of mice 
(Appendix C, Fig. 38). We did observe a trend in the increase in NRF2 levels in kidney 
and liver tissue, but this change in NRF2 levels did not translate to a corresponding rise 
in NQO1 or SOD2 levels. To further test the activation of the NRF2 pathway in vivo in 
different tissue types, we can use the transgenic NRF2-luciferase (NRF2-luc) reporter 




[344]. This would help us determine the time taken for activation of the NRF2 pathway in 
different tissue types and determine the frequency of MnTE-2-PyP treatment required to 
maintain high NRF2 pathway activity. Alternatively, transgenic mice expressing human 
placental alkaline phosphatase (hPAP) under control of the rat NQO1 ARE and a minimal 
promoter (ARE-hPAP reporter mice), can be used for visualization of cells featuring the 
NRF2 pathway activation upon MnTE-2-PyP treatment [345].  
We know that KEAP1 is a vital redox sensor and is subjected to several different kinds of 
post-translational modifications [346, 347]. Modification of the sulfhydryl groups (cysteine 
residues) in KEAP1 can lead to the dissociation of NRF2 from KEAP1 [346, 347]. KEAP1 
has 27 and 25 cysteine residues in human and mouse protein, respectively [346]. Analysis 
of cysteine modifications of KEAP1 at C257, C226, C613, C622, C624, C272, C288, and C297 
through mass spectrometry experiments would be the next step to understand the 
mechanisms of NRF2 pathway activation by manganese porphyrin compounds [346]. 
KEAP1 uses C226, C613, C622, and C624 residues to sense H2O2 [346]. H2O2 is a critical ROS 
molecule that plays an essential role in cellular physiology at low levels and has been 
associated with multiple human diseases at higher concentrations. H2O2 can oxidize 
cysteine residues to form intra- or inter-molecular disulfide bonds between two cysteine 
residues, thereby modulating the function and stability of several proteins, including 
KEAP1.  
The use of NRF2 inhibitors to treat different cancers might increase the damage caused 
to normal tissues during radiation therapy. Further, they might cause the development of 
fibrotic tissues or the transformation of fibroblasts to myofibroblasts, even in the absence 
of radiation exposure. Hence, the use of NRF2 inhibitors such as brusatol, ascorbic acid, 
luteolin, ochratoxin A, trigonelline, and all-trans retinoic acid could have severe toxicity 




in vitro experiments and would help in determining the role of NRF2 pathway activation by 
manganese porphyrin compounds in different diseases. Along with the use of NRF2 
inhibitors to test the various hypotheses, we can also use inhibitors of the downstream 
targets of the NRF2 pathway, such as dicoumarol, which is an inhibitor of NQO1 activity. 
Alternatively, we can test the significance of the NRF2 pathway activation in 
radioprotection using NRF2 activators (discussed in the previous section) that are different 
from manganese porphyrin compounds. To examine the role of NRF2 downstream targets 
in radioprotection, we would like to generate an inducible knockdown system of NQO1 
and SOD2 in prostate fibroblast cells. We would then test for changes in the myofibroblast 
markers and the myofibroblast phenotype, post-irradiation ± MnTE-2-PyP treatment. We 
would further verify the changes in NAD+ and NADH levels in the absence of NQO1. 
Understanding the metabolic network and the impact on the activity of sirtuin proteins will 
help determine novel radioprotective mechanisms in fibroblasts.  
We have identified the upregulation of SOD2 protein upon manganese porphyrin 
treatment. However, we have not confirmed if this is a transcriptional upregulation of 
SOD2 due to the NRF2 pathway activation. SOD2 expression is regulated by a host of 
different transcription factors, including NRF2. Further, SOD2 protein upregulation was 
observed before a significant increase in NRF2 pathway activation (Fig. 9) and in KEAP1 
knockout MEFs (Fig. 16). Therefore, NRF2 pathway activation by MnTE-2-PyP treatment 
may only be partially responsible for SOD2 upregulation. Further analysis of changes in 
activity of transcription factors such as specificity protein 1 (SP1), activating enhancer-
binding protein 2 (AP2), tumor protein p53 (p53), forkhead box o3 (FOXO3A), NF-κB, 
hypoxia-inducible factor 1 (HIF-1), and cAMP response element-binding protein (CREB) 




compounds, which would further improve our understanding of antioxidant properties of 
manganese porphyrin compounds. 
The use of manganese porphyrin compounds in chemoprotection is a new area of 
research that we think can have a significant clinical impact. The activation of the NRF2 
pathway by manganese porphyrin compounds would help protect normal tissue from the 
toxicities of chemotherapy. In this view, we plan to investigate the role of manganese 
porphyrin compounds in preventing toxicity caused by Gemcitabine or FOLFIRINOX, on 
blood cells. In muscle cells, manganese porphyrin compounds would alter the metabolic 
network through NRF2 pathway activation and prevent the formation of the cachectic 
phenotype seen in pancreatic cancer patients. A potential problem with this strategy is 
that it may reduce the anticancer activity of chemotherapy drugs. However, most 
pancreatic cancer tumors have a hyperactivated NRF2 signaling pathway, and the 
addition of manganese porphyrin compounds may not enhance its drug metabolism 
potential. 
Overall, we have observed that manganese porphyrin compounds are effective 
radioprotectors and prevent the formation of the myofibroblast cells post-irradiation. There 
are several molecular pathways altered by manganese porphyrin compounds, and one of 
the essential pathways activated by manganese porphyrin compounds is the NRF2 
pathway. The NRF2 pathway is a radioprotective pathway that reduces the overall 
oxidative stress and controls other major cellular functions that are responsible for cellular 
protection through the downstream targets. Identification of this molecular insight in the 
role of manganese porphyrin compounds has clinical implications in radioprotection and 
the application of these compounds in other diseases, which is being further explored in 





Appendix A: Role of NRF2 pathway activation by MnTE-2-PyP in radioprotection. 
To confirm the role of NRF2 pathway mediated radioprotection in MnTE-2-PyP treated 
mice, we utilized C57BL/6J mice (wild type) and C57BL/6J Nfe2l2tm1Ywk (NRF2) 
knockout mice and exposed them to pelvic radiation with or without MnTE-2-PyP 
treatment.  
Materials and methods: C57BL/6J mice (wild type) and C57BL/6J Nfe2l2tm1Ywk (NRF2) 
knockout mice were exposed to a total of 35 Gy, which was fractionated over 5 days at 7 
Gy each day. Mice received 5 mg/kg of MnTE-2-PyP or PBS one day before radiation 
exposure as the loading dose. During the week of radiation and the following 2 weeks, 
mice received 2.5 mg/kg of MnTE-2-PyP three times a week. For the remaining time, 
mice received 5 mg/kg of MnTE-2-PyP once every week. Mice were scored for radiation 
damage every week by giving one point for each of the following symptoms, hair loss, 
sores, tucked leg, redness or inflammation and a prolapsed penis. Radiation damage 




















































Figure 36. Role of NRF2 pathway activation by MnTE-2-PyP in radioprotection. 
Wild-type and NRF2-/- mice were exposed to a total of 35 Gy, which was fractionated 
over 5 days at 7 Gy each day. We observed for radiation damage every week and 
scored the mice for hair loss, sores, tucked leg, redness or inflammation and a 




Appendix B: NRF2 pathway activation, in mice treated with MnTE-2-PyP for two 
months. 
Materials and methods: To confirm the activation of the NRF2 pathway in vivo, we isolated 
prostate, bladder, liver, colon and skin tissue from C57BL/6J wild-type mice obtained from 
The Jackson Laboratory treated with MnTE-2-PyP for two months. Mice were treated with 
PBS or MnTE-2-PyP (5 mg/kg) three times for the first 2 weeks and then once a week for 
the remaining time. Tissue samples were frozen immediately after isolation at -80 °C. 
Tissue samples were homogenized using a Dounce Homogenizer in lysis buffer. Cell 
lysates were made from the tissue samples using whole tissue lysis buffer for 
immunoblotting experiments and NRF2 pathway activation was looked at my looking at 
changes in NQO1 protein. For RNA isolation, RNA lysis buffer from ZR RNA MicroPrep 
RNA isolation kit (R1065, Zymo Research) according to the manufacturer’s protocol. We 






Figure 37. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two 
months. Wild-type C57BL/6J mice obtained from the Jackson Laboratory, were treated 
with PBS or MnTE-2-PyP for two months. Mice were treated with PBS or MnTE-2-PyP 
(5 mg/kg) three times for the first 2 weeks and then once a week for the remaining time. 
Prostate, bladder, colon, liver and skin tissue were isolated and stored at -80 °C before 
analysis for NRF2 pathway activation. (A) Relative NQO1 mRNA levels in prostate 
tissues. (B) Relative NQO1 mRNA levels in bladder tissues. (C) Relative NQO1 mRNA 
levels in colon tissues. (D) Relative NQO1 mRNA levels in liver tissues. (E) Relative 
NQO1 protein levels in skin tissues. (F) Relative NQO1 protein levels in liver tissues, 




Appendix C: NRF2 pathway activation, in mice treated with MnTE-2-PyP for two 
weeks. 
Materials and methods: To confirm the activation of the NRF2 pathway in vivo, we isolated 
kidney, liver, prostate and skin tissue from wild-type C57BL/6J mice obtained from the 
Charles River Laboratories, that were treated with PBS or MnTE-2-PyP for two weeks. 
Mice were treated with PBS or MnTE-2-PyP (5 mg/kg) once every two days for two weeks. 
before analysis for NRF2 pathway activation. Tissue samples were frozen immediately 
after isolation at -80 °C. Tissue samples were homogenized using a Dounce Homogenizer 
in lysis buffer. Cell lysates were made from the tissue samples using whole tissue lysis 
buffer for immunoblotting experiments and NRF2 pathway activation was looked at my 





Figure 38. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two 
weeks. Wild-type C57BL/6J mice obtained from the Charles River Laboratories, were 
treated with PBS or MnTE-2-PyP for two weeks. Mice were treated with PBS or MnTE-
2-PyP (5 mg/kg) once every two days for two weeks. Kidney, liver, prostate and skin 
tissue were isolated and stored at -80 °C before analysis for NRF2 pathway activation. 
(A) Relative NRF2, NQO1 and SOD2 levels in kidney tissues. (B) Relative NRF2, 
NQO1 and SOD2 levels in liver tissues. (C) Relative NRF2, NQO1 and SOD2 levels in 
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